{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright Â© 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Alzheimer's Disease: Targeting the Cholinergic System",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "namespaces_uncached": [],
    "path": "receptors/ferreira-vieira2016.bel",
    "pybel_version": "0.13.3-dev"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Acetylcholine (ACh) was the first neurotransmitter to be identified",
      "key": "9f0ed14d4c5c91cee8b4f090c7664db7d3b24960bd4c18712aaf4055a6e1731fdc3858d42bcc33bc2ff072826df1a31d9f03aada3f84925a8f8a9d162d92f507",
      "line": 77,
      "relation": "isA",
      "source": 15,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, published data indicate that ACh is involved in memory",
      "key": "e25cfa9bd67d4706a412f9e6e272d60d97e0683ffe71c55130723839e9e14606fd41998abccdafb21fb168ebc54c35bef8722db5497659b1f60573a360cc7c23",
      "line": 123,
      "relation": "positiveCorrelation",
      "source": 15,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further studies have demonstrated that endogenous acetylcholine is important for modulation of acquisition [17], encoding [18], consolidation [19], reconsolidation [20], extinction [21] and retrieval of memory",
      "key": "47ae7b5bb92b437879c10fdc750a09a2b8e1f03cba515715abc7eae64a957189e9ee761dd002910cb97aac6bee5a4a758c0705cab3ca2429616d1dda67f71e10",
      "line": 131,
      "relation": "regulates",
      "source": 15,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "key": "2b2bf5aa3575062f68d559b81f287b26bbee3da14a815995d3801219d750c9f4a69558da3ea1d45944c6fd16237cb14b403d86d71f95b0d59f2dc616981d7225",
      "line": 490,
      "relation": "association",
      "source": 15,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stress is another factor that can regulate ACh release in the forebrain and its function on the hypothalamic-pituitaryadrenal (HPA) system can modulate biological and emotional outcomes",
      "key": "7853458645cfb4420f660e5db67bb77bf406dd09fd58e02d9123199793014c28607d17adf944af8c6f8cd36a0336d60cca4b7c64878dd92d31fb458100d50772",
      "line": 152,
      "relation": "regulates",
      "source": 15,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Similarly, nicotine can mimic the ACh effects on the HPA axis by activating nicotinic receptors",
      "key": "66a9c8ee361c71d5be75c4c21e41945d4738197b5b786b0f7a8dbf813bd9e8b024e530bd0d477631362861be6e109c60c3c778c6d442a0648a9f544ca992dc52",
      "line": 171,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ACh contributes to auditory synaptic transmission by facilitating thalamocortical communication",
      "key": "879ffa8a6dc28dee0f82138c97a173e19da22a9f9354be8eae52c6c785089459a715a099ba47bf063fd786be95a549cd8f843411be7c379b59b186927e2f9d3b",
      "line": 191,
      "relation": "increases",
      "source": 15,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ACh contributes to auditory synaptic transmission by facilitating thalamocortical communication",
      "key": "61d61e8c67e293d9014985cb3d9dba99d3c29e864488448101e39a5fa981b18a58b925498e316e346d331fb8894a403fa65b00763e0ab296e128bb04340e5500",
      "line": 193,
      "relation": "increases",
      "source": 15,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Recent evidences also suggest the involvement of ACh in adult neurogenesis",
      "key": "a2df9404adbf0f354e6ee99e29177409283dc676582308c6e72d9f2a63862a0a9c2c9c8d716dd9e5894ad824e6d0f7cc15d7fc93a4b851b100dcb84d963b0f8b",
      "line": 199,
      "relation": "increases",
      "source": 15,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "When cholinergic neurons are depolarized, ACh is exocytosed from synaptic vesicles and released into the synaptic cleft, where it can activate both muscarinic and nicotinic receptors",
      "key": "26adb63ac3418c27e0cd3b2e507082df3bacbe6d818dd780e671d86489bc90037ea9c45698f21464294d0eda2ad86663561861f3a86497986eaf53d1c840c660",
      "line": 285,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "When cholinergic neurons are depolarized, ACh is exocytosed from synaptic vesicles and released into the synaptic cleft, where it can activate both muscarinic and nicotinic receptors",
      "key": "48eb94a0ad9c5daae6713c14e748b9c5453e7ad1cc83c2517e3841f2887214360716da3da8327067fd21c085736d5098ad3b4e1d93c279f8848e83d1e40efbd5",
      "line": 286,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Choline that is released by ACh hydrolysis in the synaptic cleft is continuously reuptaken into the presynaptic cholinergic neuron by an active transport system (see Fig. 1)",
      "key": "f55525078c812f94a08c0c79ca0deace7be9528b25d3f03aff0c746539a830ac6f5078987703ad5382080a56c7b3aa445f9061b728fd0bc24b4208bab6c40c54",
      "line": 331,
      "relation": "increases",
      "source": 15,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Thus, ACh can influence the strength and fidelity of various synapses and modulate overall CNS neurotransmission",
      "key": "2f8ff9bdd22b892a78d8cdd6309f7912c414eba79333dab15a6fa486ce72fd3776a58546e701341535c2eb6033847aac1894d31d98a24487dd0343189a8cf9e2",
      "line": 474,
      "relation": "regulates",
      "source": 15,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "key": "13999f0c98a3fdb114c7195c101eea09cbc392d5d9348e2b866902f63819e82dbc7a02f6cf8f51eedc46b391408dbcb12f9db4e0c7c9983a250686216744a84b",
      "line": 488,
      "relation": "regulates",
      "source": 15,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "key": "80a238d17ea11fc0f7806bc5747c7e7ba93f10041ade1d70b3008ecce00b0ac7c040f774f8195bd01fb01062967e5929de47cee105415723342e06ab97dca9b9",
      "line": 489,
      "relation": "association",
      "source": 15,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "key": "90cfb61b93c255d00c27b722ca7e77ed5344c1498fefa675e67ea9dca12e29166fa042c745291bfe917e6316772c81324fc0fb548ffed059c0b86eefe2205531",
      "line": 636,
      "relation": "association",
      "source": 15,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Given its widespread distribution in the brain, it is not surprising that cholinergic neurotransmission is responsible for modulating important neural functions",
      "key": "df59649a009037615ca1c4c5cc35b6dc3e71206331d590a72ecd2bc9a4ae4757c34ab8cba92cbc4c7f953d8143179483523724f59a730902fc9f0bbffc47cfe1",
      "line": 84,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 72,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "25b66d0d63aeaad7975ae36ac072b4d3f33b98a1d343e27cd3ba3b3eea01f227df67eeb70400bffcfd521c5785141dd2057f64a01e16791f6f323e644e392c94",
      "line": 90,
      "relation": "association",
      "source": 72,
      "target": 154
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, the facilitation of the cholinergic transmission by using the cholinesterase inhibitors can improve attention in humans",
      "key": "3bc5b67fe412ece7220875359e8c6fe0d013938be8547473f75b6f32b32358ffd6f8d5810971c16fa56d715d93414c29ff1371b488994de6f6f7a5cd0316b42b",
      "line": 112,
      "relation": "increases",
      "source": 72,
      "target": 154
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Disruption of cholinergic inputs to the cortex can impair attention and the use of instructive cues needed for decision-making related to ongoing behavior",
      "key": "d02338c803594274b25ea37e874e2bd81b3adc9e80220b6b244bfcef52718483de05a127a25bad6f7ec552811ea9a4e23ecadabfd8b897f1a887d836b75c9175",
      "line": 643,
      "relation": "increases",
      "source": 72,
      "target": 154
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "d8858b003255bb9ff4b880b1949d142bf90e076552c165c8a8d2abd00a3df746fa16f37e0845d3d0aee2798ac13a5f85882e6ed130a0c55b2ff331dd3bd67b51",
      "line": 91,
      "relation": "association",
      "source": 72,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the cholinergic system plays a role in the learning process",
      "key": "3a4ee8042be8ef76378c1df480b121ae9cf3a32e731f69641e58dd3e70c31d0bd17d1cf5fa3992f1abd5906b524bfa44176c831bb2bb34c0d6543a787f2efb33",
      "line": 118,
      "relation": "positiveCorrelation",
      "source": 72,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "5f93501f724701e46164b68404979e9b8cbeab2ec4d930fb4ed96910a488dfd4309855f59282cbd184b1e2a1b207bc23073ad077b9ea0856d39d2aecaf42e71b",
      "line": 92,
      "relation": "association",
      "source": 72,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "65a9742a7fc816bd26a42ffe0f0d1668f5b2582986128c06240f4db0c2a864e4401afc0a5b7644afa477ea3ad25ab1892b3b8680a2f248b7a231fb7a07a9284f",
      "line": 93,
      "relation": "association",
      "source": 72,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "9badb89e489a419b481a26cb8fadad1c24360f0543ce193b1c47afe5990bdaa658473eebc127c90277c794f9bdcb7dc17fe55d7f8bae6895dbfe82cdee003b87",
      "line": 94,
      "relation": "association",
      "source": 72,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "140d82ceb51177df296dc95eff2f7db624cd87fc123045ee9ab4d24a5f0c5d314e3db94be99747e2d42c18209feebd4e573f98017198a37b2e9ee358a4a9e313",
      "line": 95,
      "relation": "association",
      "source": 72,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "3150defe0ced5a780ab4695670321f7876d9d03ab5704923ee961241b498a0ff0606ba9fa7ba0f83a035308c9180b4ea8d2811c9083c91ad086a879d4080a7ec",
      "line": 96,
      "relation": "association",
      "source": 72,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Another important function of the cholinergic system is to regulate the sleep cycle",
      "key": "068b0b923704ba788e98d0eceb5b9058ca4c2bc20365a0584bcf3d44eb8e7afe66ca4493c90f8a0eaa9a31b5b475b139efa1d0d48c2e3829c5378a3c13111c2a",
      "line": 177,
      "relation": "regulates",
      "source": 72,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "1eaa3960dad9227e5c2b48c840649407bc784ab419316103d20616dfde475673a8d87538051f1bcadcfaa04ff468329506a63084abe1a4876ac30f49fbf3d14f",
      "line": 501,
      "relation": "association",
      "source": 72,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "c4481843d7980f5c0ad3b3a76068f76b0fee6a04647adde0182a2f2d5448fa25eada2fea25f3ebc002a5989308b7bf25003f8952037ff291620d4aec94f5a609",
      "line": 502,
      "relation": "association",
      "source": 72,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "key": "59f141070092422173205fe7cddc7daefe5d8e44496eb42905f7e52f64fccb412fa6dad04eee1a7a5bb1edc7096183ac3c80c6664abdf4a9babe1a89af1a7f7b",
      "line": 634,
      "relation": "association",
      "source": 72,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "key": "b6e9b5ac42f59917f8e8b316c18b9f4d4194a0752147105812ed6a035a32673e62dc753a4c994dd100c05a1d6249ae8fa7a61a12a2b3e4af3cf742158dd947e9",
      "line": 635,
      "relation": "association",
      "source": 72,
      "target": 156
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "3152dd65f5e3d9f23064ecb51e8717ec0f3b4c1c7bcbf2be09a2be9a502519d70144b02a6d2a9077ce1388d06ced609e30ef6010828b8f39707b424a0fa093b7",
      "line": 90,
      "relation": "association",
      "source": 154,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "e724f8eacdbd7e1b0271fc836cbabc9cd54ca2d7cc448d3d71f7a339b6495d1c4f637c4bab3e254ecee88432bc4670c05626dff0705bf9aeedb71d3e20ea373f",
      "line": 91,
      "relation": "association",
      "source": 76,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the cholinergic system plays a role in the learning process",
      "key": "e0cb0fc29096e9f3488340879f241f874033634444e166d42abbfa5ba26e384d5b8b75f5981bd9b9665333800dff4fc7dcba8f0386b21fd83e991761b90c68ee",
      "line": 118,
      "relation": "positiveCorrelation",
      "source": 76,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "key": "1ba10693dab4d9e3c0a642704b9d0dcc09b9607dcb2fca39a247ef6170961eadbbcffa6bf14079b0b7ef60aa4be7a6b1341640fd91de38162a10e7cafb300d1c",
      "line": 489,
      "relation": "association",
      "source": 76,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "f4daed5ce170fa0a5e52c8febcd76651fbeb05c7966224e0e8d4102ac0937b822798375bc573ff57c56642e0ee7e6e53b05552df9beb8e7355e739939e25f5a1",
      "line": 92,
      "relation": "association",
      "source": 77,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, published data indicate that ACh is involved in memory",
      "key": "a397dba15cd5c6991b5138698336beabe1363171dadf2fe10cd997634c5d0bf9bb14d6756044dedcc50401415b6b6f4bb44f5b592a05f42862fd5db4bfd66560",
      "line": 123,
      "relation": "positiveCorrelation",
      "source": 77,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that the role of ACh in learning and memory seems to be related to the regulation of glutamatergic neurotransmission",
      "key": "41c6fea3acc69c110d20b54b243cf068f092b5d16e82c05417c519b23c7a39368104ba22d789630434539a336c6677e7b1a8cd7c251127ed4205cb6a70e5d3cd",
      "line": 490,
      "relation": "association",
      "source": 77,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Nucleus of Meynert": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "key": "1f4011f4ac7c31178d83597e03f17aa0a2da14d5f528fa433006ba4170e021b09df56ceaeaf262853d8ae2ef03e878f9a350e208b6884a6e37c8618c4fdc7858",
      "line": 140,
      "relation": "positiveCorrelation",
      "source": 77,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "key": "791a7c1d8a379a34535f48e66caab372eddd59467a2834251bc1ecda94f1bf152d3e3aa8fdfb8837787981e53aeebf0c18224e6f6a703fe82b09b5b09a1cc99d",
      "line": 143,
      "relation": "negativeCorrelation",
      "source": 77,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "key": "846e851871772f84c64f458c97b74b6a7f430b30d852c506a342f61458d49f050ab9aa31accd3d7a938fe5719cc6260a62b67f7aaba838a26837705d3521e771",
      "line": 718,
      "relation": "association",
      "source": 77,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "key": "9a3dcf89877c24df5ec01af99fc8c046de4b866b33dcc8bada7d17847580a3644986c190e959c0f2d0181e49fc4364b800d1154f8b454b7bfd88a216269960c9",
      "line": 719,
      "relation": "association",
      "source": 77,
      "target": 134
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "26982bc6d6696ea95d1dd35923aaf9fd8ff62620d358fa90f93e419c1122a94a921a172dc42f3d3e3a0ccee37474ee3d415a57996b021f73ce4bb6c0ac74ebb7",
      "line": 93,
      "relation": "association",
      "source": 70,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stress is another factor that can regulate ACh release in the forebrain and its function on the hypothalamic-pituitaryadrenal (HPA) system can modulate biological and emotional outcomes",
      "key": "e37b44215fdb73d06f2cf96fa75aba2f47fdc3080f883b87482b41b4046c1e4fd9feebe033553b3a4f9fdaaee20b6fb07f7acf6b2271eaefe9bb03e2e60e7e0c",
      "line": 151,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Basal Forebrain",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "regulates",
      "source": 70,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "2a4b5510d2f7e4e14576c48e8ec9a362c5e0a3965cfd2c707be70cccb521619cf9562e7a49b32300d9ff215c2c8fe38b048157b173ac3efbade91aa5dba1979b",
      "line": 94,
      "relation": "association",
      "source": 68,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "512d0cd0e5919515dda3f5bbc5b9323076b024ed14197edb58822e2937d62156f64f52a855bc80dfaeee3478d608f2523d43c5f8f5ad79f23f63e685ea8e3ace",
      "line": 95,
      "relation": "association",
      "source": 67,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The cholinergic system is involved in critical physiological processes, such as attention, learning, memory, stress response, wakefulness and sleep, and sensory information",
      "key": "72e6a0d5510aa2bd5cde77eae47d53950fe5fbecd1d0b5486dcbc059750429f0a8afb948e30d415aa9904a816ac13d9f3e270615fe49c22bd72db9a22bc7ca5d",
      "line": 96,
      "relation": "association",
      "source": 71,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Experimental data using non-human primates and rodents have demonstrated that injuries introduced to basal forebrain cholinergic neurons that innervate the cortex lead to attention deficit",
      "key": "871c0814ebfa9eca21a0ff9b726b68b3e88daee4c210eb89a39c817298540cd5cd8d279e7de14211eb8f233a4685b45acab70e6f21566c58bb59f27664dd7d5f",
      "line": 103,
      "relation": "increases",
      "source": 45,
      "subject": {
        "modifier": "Activity"
      },
      "target": 154
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "All these cholinergic alterations that take place in AD closely correlates with impaired attention and memory observed in patients",
      "key": "2a05a7ba7ecb244269f65fc6c10d2e168e08ef0d56e9d11581d22002df8eb9115c0c04c32bb77c6b305158dff727ff0385461885e132d7a120cc92a51cc7c2ed",
      "line": 745,
      "relation": "increases",
      "source": 45,
      "target": 154
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Nucleus of Meynert": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "key": "3c15df1091c6e687be4d396e722dcdb638be1ca3915183923a1709a26cd6512973479d9d5b35cb07f8b96cfa5c8938dd87323ecf1c59b806e687e03db0a072bf",
      "line": 140,
      "relation": "positiveCorrelation",
      "source": 45,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "All these cholinergic alterations that take place in AD closely correlates with impaired attention and memory observed in patients",
      "key": "56ad18496e76836ef20cc372ecbd431584d0ce6c650deaa1c73f9c621e3067352eaf06d9621931f966c5d3069925b9d2e5ae88f4651356a9ba9d70020e84bd32",
      "line": 746,
      "relation": "increases",
      "source": 45,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain Stem": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that stimulation of cholinergic neurons in precise regions of the brainstem can promote REM (rapid eye movement) sleep, dose-dependently",
      "key": "1eb1ed7519a16128a4abcfffa44fd85faf41168327583925fce82a11218db2788600cbe0f3a7b3ef397f104b89416657590f1dc1eac69654f02ae8150e7fa603",
      "line": 185,
      "relation": "increases",
      "source": 45,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ACh synthesis takes place in the cytoplasm of cholinergic neurons",
      "key": "e3beecb2c466e17e9aebfde3dc46e9fe41c253b911826e210c89173f6be5d151c9f60b9afa1d0934d70e3bf8271c69844de3fb35a6540becd6511cf8061494ea",
      "line": 205,
      "relation": "increases",
      "source": 45,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Although cholinergic neurons can synthesize choline, the de novo synthesis contributes only with a very small fraction of the total choline that is needed for ACh synthesis (see Fig. 1)",
      "key": "149d40ec848e05688e6bd7f8f7fb7c19e3343be2fc8e562dc3fe0eaea55cc23363a6c4b8fb893e716b22870f1ad7f3401774b9784110374065b3932fc2d7a435",
      "line": 228,
      "relation": "increases",
      "source": 45,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Cholinergic neurons secrete AChE into the synaptic cleft, where the enzyme is normally associated with the plasma membrane (see Fig. 1)",
      "key": "4554a57f070090f0c11c82eedb03926ec48762af246a8fc232e5cfbda2d3560e3b466f618b39783c4c7d9dbae9e30ca7574454917c7f9ac2b457e451227bd919",
      "line": 301,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Synaptic Vesicles",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "synaptic cleft",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 45,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms",
      "key": "c11bffcc78b68849a331d0179af3aa826449ec2dae2bb2453239c1a3b6ead54cfc5b1d9934070e131bf28a83948b10b66e8fa6c7b69919e5ffae9e38535dae14",
      "line": 666,
      "relation": "increases",
      "source": 45,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms",
      "key": "d47957964fba1c27689814a78d9f954ad704b1e0c7ed38d328476a06181994f353347d84d3e467ae22f72549ed2426908b4142a0c6c845c4b37329d766fe046d",
      "line": 668,
      "relation": "decreases",
      "source": 45,
      "target": 153
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been postulated that the loss of cholinergic neurons and the consequent impairment in dopaminergic transmission could be the main factors underling AD-related psychiatric symptoms",
      "key": "5c05d30034efa15abec473b7080b07bbbd3763f7fd37ccf56d1da0388e402878bb84909a8f0d96483aa34fdafd3f149032e0028a7d1a80a04a88c13c54a3b6f2",
      "line": 669,
      "relation": "decreases",
      "source": 45,
      "target": 157
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "54b2ed8fd1c8d1bb071c59edaf822681881697dea91f5ce2b7a1826cf474f2cd23012c21eb283e890dfece364dfbb49ec8ed4ae06fadc143a4022d86016872fb",
      "line": 689,
      "relation": "negativeCorrelation",
      "source": 45,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "5fffce02f893429643111ebaaf9322acc939213886646b416e2b94e7822d83bc60c0afc4f40786b978d52d4a6c29f4cd04d4c155cf609411bb2c8e0c1284987a",
      "line": 690,
      "relation": "negativeCorrelation",
      "source": 45,
      "target": 150
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "7a5976ecd9bbdc9012bf6fc6a15e4d9966ff4c0b9fb263e6dd521cafa1ca1bb1b36a36dc0fc4702aa8f5fb284558fdea14f5af7d782739b498ece328e38f6d4d",
      "line": 691,
      "relation": "negativeCorrelation",
      "source": 45,
      "target": 145
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "7097943b85c3e18c23fc2e9a7dd6d56677b1a77f58e4a362c050cf82212dfb73c3076e8a135f4d4fdd860c759c333cde72d170afb022a1c0f5c1e454ffe12a0b",
      "line": 692,
      "relation": "negativeCorrelation",
      "source": 45,
      "target": 143
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "7307b285e16a1ecffa2b359547961fda60ea6997c2d9ab21e833f50b4635eb5f795970c9de2405764965af50390a6953fe2ccf504e2b874941fbce82fe89efe7",
      "line": 693,
      "relation": "negativeCorrelation",
      "source": 45,
      "target": 152
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "6ceffc1c68ebe0202ed210f1fc291d90541edb758e1580946eeaf5d5dea42cb64a34d078eefeecf0103eb885d958680c1877a89ebdf55ae183bb11baecd09618",
      "line": 694,
      "relation": "negativeCorrelation",
      "source": 45,
      "target": 149
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "c63cc22036b5dc83ba04b3c2b844d3969baa09cfc1dc5e5ffa521962b292ca0cf0a54e78a6570b8a2c4523d2de24f96a093df33ba30fc4583e629bfd997b5d98",
      "line": 837,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 45,
      "target": 105
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, the facilitation of the cholinergic transmission by using the cholinesterase inhibitors can improve attention in humans",
      "key": "17a9b06b8816902ed23d47a5a9172640605e8ea5df44aea3e255c544fa1d3bb8e78017589614344d7f9394248638faebd56a38253836ab038de1e10b6bd540ae",
      "line": 110,
      "relation": "increases",
      "source": 3,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The importance of the cholinergic neurons from the nucleus basalis of Meynert on memory is highlighted by the fact that the specific degeneration of these neurons takes place in Alzheimerâs disease (AD) and contributes to the memory loss exhibited by AD patients",
      "key": "635e03d1c0adf3d4d4b568b58ad54da286b2582f869a42fec0e67e5d0194c26513fa1dc7b9076d38af3bacee489b7188f0397a82c34766bf06e92440aaf120b9",
      "line": 143,
      "relation": "negativeCorrelation",
      "source": 79,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "befc6e793333eb7ebe8ebc3f61a16e1823dae2b16816e36fa696d867c0cf870da2dbff6f94228bf6df521b57540557b6449eee7d21587729d33afe543263d2e8",
      "line": 500,
      "relation": "association",
      "source": 79,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "70731a14bea3003fb5304200c09f8317d6e2a256be0f9faf641fc74b8d5071a07afad1b97397ac24778327be60b31cd0b3bc6b108cfdb653a03a33be30a43ff0",
      "line": 502,
      "relation": "association",
      "source": 79,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a work that evaluated the function of the cholinergic system in mediating the response to stress it was found that treatment of rats with the antagonist of the nicotinic receptor, mecamylamine, attenuates the activation of the HPA axis in response to a stressor agent",
      "key": "b89820c0ce369e630173d1e6902026bf160d8967531bd7c000ce58ae9d48d920923f2ff35c5f4406756ca2d1e00e6002950207c62a5bb77d95702147249fda63",
      "line": 162,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 56,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Peripheral Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In the peripheral nervous system, activation of nicotinic receptors leads to rapid synaptic transmission",
      "key": "ef215782f42a54a1ab219411fc9e43fa392a29c3f29d17d8961d986411e0347c5ae2fa269fb1c442c6881b151989ba00fdc160e37a51b79cabd8892814396dd9",
      "line": 437,
      "relation": "increases",
      "source": 56,
      "subject": {
        "modifier": "Activity"
      },
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Membranes": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In the CNS, most of the nicotinic receptors are expressed at the presynaptic neuronal membrane and their main role is to regulate the release of neurotransmitters, whereas nicotinic receptors expressed in the peripheral nervous system are mainly post-synaptic",
      "key": "71c2d6f7e83db65405bd4405e11fd2b14149f8f088798a07f3c820e1a989c86d942da19b20bbccc81e956c28e91d719e87451c43ff2f25d5da9f9e0b26121548",
      "line": 447,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "regulates",
      "source": 56,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Central Nervous System": true,
          "Membranes": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "20085b084c79b6d8bccb96290825014e28b91044932c330f1ae2f915b6d1392ae704f2d69d10f1eb7a88f7db656f14d02233e8feed6766f32945cd104ad450c4",
      "line": 457,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "synapse",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 56,
      "subject": {
        "modifier": "Activity"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "However, further studies have demonstrated that nicotinic receptor activation can lead to an increase in AÎ²-mediated tau phosphorylation",
      "key": "cf9ed63847a7e2cee5766e18ac202f917c844346552ea0b906774c259d0cb5475a12a3e076633fead30790cb79fb11cd28f2646d5f40383ec2f16f030eddbe9e",
      "line": 891,
      "relation": "increases",
      "source": 56,
      "subject": {
        "modifier": "Activity"
      },
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a work that evaluated the function of the cholinergic system in mediating the response to stress it was found that treatment of rats with the antagonist of the nicotinic receptor, mecamylamine, attenuates the activation of the HPA axis in response to a stressor agent",
      "key": "8eda9b64bc4225e5413cf2e46da399e0c839710b1d3e3f682867b937f02b0bd44497a60ecddf8ee2160a4a124dee6f243896ba24f04c19999ad7112b7d57a0d2",
      "line": 163,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 12,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Similarly, nicotine can mimic the ACh effects on the HPA axis by activating nicotinic receptors",
      "key": "b3e0f99e4db74865be24e5a9c6a00ceabd20f27f1a936e7c9f1959d604a6df446c4c0fa2e1021668e7c754a25c7bc3522f3616fcf62f6e1b25aec6e383483524",
      "line": 170,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 26,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The enzyme choline acetyltransferase (ChAT) can synthesize ACh from choline and acetyl-coenzyme A (acetyl-CoA)",
      "key": "dc1eb6a9d079f7b68cca182beb17b4beaab6ab29397f3da0f21b733ab0ca55b472238c42985f36003bf3d294733a5c4066ba140e0387660eebfb6677019ab407",
      "line": 212,
      "relation": "increases",
      "source": 103,
      "target": 159
    },
    {
      "key": "8ffddbe50788f76436cb12f173efb7d3c2bf92b1d683b765a54c7e6257ff4307d359b532deca5ea31f1da7f5dc2ea7cf9b4edc1c1412ebef1d0b65afa8acae41",
      "relation": "hasVariant",
      "source": 103,
      "target": 104
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, Huntingtonâs disease appears to be associated with decreased ChAT activity",
      "key": "31f6e49404da88dee9caadb74757dd4006349744058d12d57899ca7a6221aebabcbe2e5552593ec2e0e54411364cc51eed115a0f8cd95e4e0d8fa153160366c6",
      "line": 700,
      "relation": "negativeCorrelation",
      "source": 103,
      "subject": {
        "modifier": "Activity"
      },
      "target": 146
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, it has been demonstrated that ChAT transcription is severely diminished in the remaining cholinergic neurons, which leads to decreased ChAT activity and progression of dementia",
      "key": "be0a6e91bfa775c1f665c4e1fcce5ea560f9fbd6b55fc7e672d69b22161064d9d1864da4cdc4cf368e323d8bfe2e39f7cec2ae678fe32af0409d37c9e9e67516",
      "line": 736,
      "relation": "decreases",
      "source": 103,
      "subject": {
        "modifier": "Activity"
      },
      "target": 156
    },
    {
      "key": "b7a4038970fcc90b38a886ddfc984321f4602a9d4e8ea04407efe739116a29dbbf69e25e6a86466da85ff080d45a78e87339f82d93511faecc27812ee2b24f56",
      "relation": "hasReactant",
      "source": 159,
      "target": 4
    },
    {
      "key": "0dfcd2b8ee4ab08b59dfb48bdf0dde698ada7e0c914debad30a5142030ab1f39b23aadaee50f095bce2454d169da52c511557f5d3ba368c0926911eb51cd78cf",
      "relation": "hasReactant",
      "source": 159,
      "target": 18
    },
    {
      "key": "648351a9cc77a8bc75462b2eeb17d36f2a93437a782f4899e188773b46b6e2475a9047a343b6c6d1db928666d1c661358ffa6cf67feaa5a372fe7d53a87ea260",
      "relation": "hasProduct",
      "source": 159,
      "target": 15
    },
    {
      "annotations": {
        "Cell": {
          "cholinergic neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "CHT1 is mainly found in cholinergic neurons [92-94] and is responsible for supplying choline for the synthesis of ACh",
      "key": "ebbc08ce7e7fb7e9409d83e3cbe24ddd2fa24dc462c130f893f1cf61baf28a6db12d0440b63b518da0c255e4a287e5fa8f0bc43966b25eeb1d9bacf94513761f",
      "line": 350,
      "relation": "increases",
      "source": 18,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Following that, the neurotransmitter is transported by the vesicular acetylcholine transporter (VAChT) from the cytosol into synaptic vesicles",
      "key": "9134001b743f3ccaa81d0bfef3c985854fd3b39e7278a2b5034e239aa4650818e33b24c2c14893c5e2f5d52a64255ddf531423a90df5666a11a531fe34248bf4",
      "line": 220,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "cytosol",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Synaptic Vesicles",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 131,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Each molecule of ACh transported by VAChT is in exchange for two vesicular protons, which leads to the fulfill of synaptic vesicles with the neurotransmitter",
      "key": "7334981d78c24f48f20f6ab713d29dd9912b59f09538698f1b67ea79692604802d3844a53f429027809c3a4426346adae0252f291e3a6ea7f942ad94db39dea4",
      "line": 245,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "cytosol",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Synaptic Vesicles",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 131,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Each molecule of ACh transported by VAChT is in exchange for two vesicular protons, which leads to the fulfill of synaptic vesicles with the neurotransmitter",
      "key": "91d1a4d1f6fda0dcaf11d9d1b666c8697807dd7c142d4707c8436eb2bf3130414a4284983d5d9d30100198e3622240a48010ab44a152131349ea452e642fe4f2",
      "line": 246,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Synaptic Vesicles",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "cytosol",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 131,
      "target": 28
    },
    {
      "key": "985719f7a52ee222821cb90b9acc9df6b63c22fdce6df4d0ff1afe6fa239eed254dfc8b83c962a98e628ab4b4154b0efd5423069ccf82a46a4c3e8a6bc9c9425",
      "relation": "hasVariant",
      "source": 131,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ChAT activity is regulated by neuronal depolarization, influx of Ca2+ and phosphorylation of the enzyme by a wide variety of protein kinases",
      "key": "14a329be549b8ac4b95be68da9449ffa7cacd1e00d17ce8ec22ea0af14fdd0522c0d6560efff61070eb9dc24eefd97b99b57f9be32df9de49bfe1ca910a12edc",
      "line": 235,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 66,
      "target": 103
    },
    {
      "annotations": {
        "Cell": {
          "cholinergic neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "When cholinergic neurons are depolarized, ACh is exocytosed from synaptic vesicles and released into the synaptic cleft, where it can activate both muscarinic and nicotinic receptors",
      "key": "306d87b823754fc9eb03f3e07a69b92c915bf524f4d4c1bd21cb23b02aec502d85017c2936223f6f08782977bceb36dfc0bd973e788ba65a7216a46325a3b3bf",
      "line": 282,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Synaptic Vesicles",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "synaptic cleft",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 66,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "422e6ebb48d8346bdb90ca9c2c1c78e8a53f07c9ddec76b6c819e4200c3f08c4f5661735d3161b0a1e115318c58764dffb0c2d00bfd76bd241dd9390b797d480",
      "line": 384,
      "relation": "increases",
      "source": 66,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ChAT activity is regulated by neuronal depolarization, influx of Ca2+ and phosphorylation of the enzyme by a wide variety of protein kinases",
      "key": "8520c30a6242a0b102f8fc74c80f2ec0f0d724ed6d0d1227c7f231408620a81f8283889d28beccd8a5f54710411325499c87c60794763b18dc0ff29e4d1b4dcf",
      "line": 237,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 62,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ChAT activity is regulated by neuronal depolarization, influx of Ca2+ and phosphorylation of the enzyme by a wide variety of protein kinases",
      "key": "dc9e1922ae9c04d5c4a1f8e58f555ddaaeb3dbbf11b126446f9b2324eff4b95f631b6314737adfc5663f9e27efddeeaa317f6e11b5141aa030badcccf869219f",
      "line": 238,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 104,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The vesicular transporter activity can be blocked by vesamicol, which is a non-competitive inhibitor",
      "key": "239be61f70b2bce3ed160981d3d62dc3d06c4d9b415b5b6923d77e66ec7cda05613c5bb17a51783612e5e2fbaf8129b16b71c92afaabef77679cdc42a6a3ad17",
      "line": 252,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 131
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The vesicular transporter activity can be blocked by vesamicol, which is a non-competitive inhibitor",
      "key": "4f4d56c6f354ab9a97cef791eccd1b1bf2485a41cbd22dc13ffcc6579c68745a2071baba651b0de10a84c3876b675b80f9c44180118c0fefca00b100f8206da7",
      "line": 253,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "cytosol",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Synaptic Vesicles",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 1,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, PKC can phosphorylate VAChT and regulate its vesicular localization",
      "key": "5bab3c14764b3a3e878a061ff13c17fd8c7a54ad0b7b58b042749ef09f033bdc34ed7a3b78666a8e6c4cd5c7f52573efb971030653fa0dabfa086cf4ad100826",
      "line": 259,
      "relation": "increases",
      "source": 99,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "key": "bf4f4f647f9251f747d6a6f1b5363805c1ad0e4a12bf36c1887c48e3067c25f66366d70e176c5fef0cd47a0bb2d16a0c215b720bcacf54ad840f347e71c584b2",
      "line": 511,
      "relation": "increases",
      "source": 99,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "A VAChT knockdown mouse model, expressing about 68% less VAChT protein, shows major neuromuscular deficits",
      "key": "d237dd533aaa3bd931d60190942ffa7aebc471e03b0b5d1f215b5052e69cfc018c43f7be270c4c0ddcfb677530eb7d888fcde7131be5f93db98922ada563e650",
      "line": 266,
      "relation": "decreases",
      "source": 140,
      "target": 148
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Furthermore, cognitive impairment can take place even due to a mild decrease in VAChT protein expression (about 45%)",
      "key": "40d0a9e0368172f9b9f2532a2c41deffe131652a6ac83998a40a76117b44be553cb8cd71156aa131d2f2c3bd0d611b56e678e034828349cd41bce520a155b394",
      "line": 273,
      "relation": "increases",
      "source": 140,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "a45c193f42cfae6e5c53ffde7ae3f8c05fb79d7b6d53e5585a690927d1ec7f77c4e5233d197fcfcae6674377743581323e3b0b6769bc7be5e947e1a537a8d113",
      "line": 499,
      "relation": "association",
      "source": 75,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "1014c8016be9d6f9ba1572755f1749e5975c39f6836f913ffeaec0895f852ce242bafd8d8be24d2c91f4bae01d53035464ed1c26c74f7268a9d1d2f57dbdd635",
      "line": 501,
      "relation": "association",
      "source": 75,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "key": "427e051845d20aced0ec5eed999cd2aefac70e9abf7c3695a68c3224c2c92cf1ec992558829dace3e12de7e489575c5d82ae85c9575a9af9dfddb1d6fef66040",
      "line": 636,
      "relation": "association",
      "source": 75,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Muscarinic receptors are G protein coupled receptors that are capable of modulating a wide variety of ion channels",
      "key": "1e1b44ab0db08b16149db0f8735ca2306de2730260319b6ddfe010d91ff6d7059eddc82bb65f1034c1f25330093d94e8be11423a7ef4346b9df02c50709cced7",
      "line": 539,
      "relation": "isA",
      "source": 95,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Muscarinic receptors are G protein coupled receptors that are capable of modulating a wide variety of ion channels",
      "key": "f4c29241dd8bba5ba02d2a8def19c0a0654107f77ac36e26ab116ab8bc8e28a074bf616938f3c973a62b53dd44b16346e93aa2835bc095b4179b2a3379348d27",
      "line": 540,
      "relation": "regulates",
      "source": 95,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "As a consequence, stimulation of ACh muscarinic receptors can promote the opening or closing of Ca2+, K+, or Cl- channels, which might facilitate either depolarization or hyperpolarization, depending on the cell type where these receptors are expressed",
      "key": "1d15481e700e6445a140fbef03da0b92a4eb888f1d22d55fcb3799287e03c77bdbf98cb5d1bba0411fd3226c732635dfd8055101623ec1bc4619dd0d6ef15c72",
      "line": 588,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 95,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "As a consequence, stimulation of ACh muscarinic receptors can promote the opening or closing of Ca2+, K+, or Cl- channels, which might facilitate either depolarization or hyperpolarization, depending on the cell type where these receptors are expressed",
      "key": "2980e74f704e72ffd9818b97b12397b0e0df571cf2e1498e0be2332ec4d7431f46d248f93f1af11fde3f8b0431052aed0ebafa53ff46663d8d4d4650cfc89bd2",
      "line": 589,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 95,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of muscarinic receptors can block various types of K+ currents by inhibiting many resting and voltage-gated K+ channels",
      "key": "bd0099ac3479d1d3711e687c795a35e1523719c658ec01230e4ed94484d2028b7ed202d59d0d9c0a1dfb9cbf2fb199f96199dd14f347075326fc9e9c14104946",
      "line": 597,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 95,
      "subject": {
        "modifier": "Activity"
      },
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "As a consequence, stimulation of ACh muscarinic receptors can promote the opening or closing of Ca2+, K+, or Cl- channels, which might facilitate either depolarization or hyperpolarization, depending on the cell type where these receptors are expressed",
      "key": "b6c71b45ff5cab0f9c35fc3b2822a01fe76f327efb47907279d19fb7aaf238ebdd321ad73c20ed8f964c8d6771222ebafe19382136a12a6b4d089cafddbad0c4",
      "line": 590,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 95,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to decreasing K+ currents, muscarinic receptors located at the presynaptic region can also inhibit GABAergic neurotransmission",
      "key": "44325fef0cde24eb69dde0466c5bb92203712a8d0ac429c35db69152b7ae6c1900145cb57f974156012e91106eca472e7eaadc04f707ba2e555e7c33adc4c328",
      "line": 603,
      "relation": "decreases",
      "source": 95,
      "subject": {
        "modifier": "Activity"
      },
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Agonists of nicotinic ACh receptors can improve, while antagonists for the receptor impair, performance in cognitive tasks",
      "key": "49a3a336270a07883355bab9ed7311abb82cca061d95538b19812a194652b125d4c6c73ddc3b8faa6a738c71baaaacdd407caa4cd0348ef6ef9764990b7026f1",
      "line": 481,
      "relation": "increases",
      "source": 96,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "51b0ecb7b5bc5b0eb923adfd1d260bcfcd7eb859d0018f0c1067fc2597f58b7fa635c9851cb731ef05b9d01bf7a94316ee6ea8459ae0506ba6700b72e0c4b48b",
      "line": 503,
      "relation": "decreases",
      "source": 96,
      "target": 79
    },
    {
      "key": "ec251192651c9563821f6298d2c0070c05bd62009f6aad9b68b808d708b03be44403e3b07acc8008085c782febff65bb11a20e33dfb31b4fc646806c059397e4",
      "relation": "hasVariant",
      "source": 96,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ACh present at the synaptic cleft is rapidly inactivated by the enzyme acetylcholinesterase (AChE), releasing choline and acetate",
      "key": "2f1f691980af0304228e471307abce2a70736510d4e3a0417f8ce51cfb89f097072a5819c60173ea7d6c1a128d5e54af6883355ff7bf82f5f1fd9eabbdf6f8d5",
      "line": 294,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 101,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "ACh present at the synaptic cleft is rapidly inactivated by the enzyme acetylcholinesterase (AChE), releasing choline and acetate",
      "key": "f38b9a9d2e6656e022b7795b6b834f37d8bd457b3b6cea90f1caa51ee5b5226cc8ed5ab888f007f298c912c27455de835bac0679a30bf84a780ab4255af76a3b",
      "line": 295,
      "relation": "increases",
      "source": 101,
      "target": 160
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Furthermore, some evidences also suggest the involvement of AChE in the pathogenesis of AD",
      "key": "c75a741a50f03c009c7818d7ec805299bff36be8602dee220da75706047fff97d7f81327d961ff9915620693cc74e7252ae53b609322eb22631f5158beef85ea",
      "line": 753,
      "relation": "association",
      "source": 101,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In this work, kinetic analyses revealed that a structural motif in AChE (a hydrophobic sequence of 35 resides peptides) was able to promote amyloid formation and its incorporation into the growing AÎ²-fibrils",
      "key": "3d20202d1373d375074e6b20a8191530eaeba18232aeb0c42d5c82d798f061febeedbca9990557cff98e63c0d19b0c4b75056fe798b83d344110b33a84e5e6e3",
      "line": 766,
      "relation": "increases",
      "source": 101,
      "target": 6
    },
    {
      "key": "8fa8aaa5b29aa56c106b1fdb243fed0b0c01276c1a22e7ff74cbcc1e0646ed2edfb7623455745142dcf387afa90a3d9a6963c69614017443f5a2bb5b50e8ce79",
      "relation": "hasReactant",
      "source": 160,
      "target": 15
    },
    {
      "key": "9f7f1f3543540f275d2f8baa7ab4095849858e13cdd631d7bf04c761bbd3c1d4c2bb9e350c1c84ff2ab1bc004a33aed57a87e2713e5cf867b5cd8d5dad335a34",
      "relation": "hasProduct",
      "source": 160,
      "target": 14
    },
    {
      "key": "047f68ef276dda59a670e84550acbf50d53018921a51fe8237537d0fb5860e861927eae3563e63a07201c0b33906f4e0c8be4d67f898ddadd52769a225e52082",
      "relation": "hasProduct",
      "source": 160,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The organophosphate compounds are irreversible AChE inhibitors that are used as insecticides and nerve gases",
      "key": "a008815f15239b6ce004b16d9153ec6ba51eebfe96c3bcc35cb7bfe0ce7ac0e41d55a0cafcdfa5472ee9721c69aa75611a0a63e729bbdf536bce431309ba6b8b",
      "line": 307,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 11,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Thus, antidotes, including doxylamine, can be used to speed enzyme regeneration",
      "key": "16d76e848888b84db4627db5afdd55c18add1b861728798fd3724615d1c22a068d4b43ffd6ff6598c5e8ada622a36994f0d1c4fbfcb8da5cf664999b987b1181",
      "line": 314,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 16,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Thus, antidotes, including doxylamine, can be used to speed enzyme regeneration",
      "key": "7f677693bb106ae427e627da5fca1ac32aa18927fd277fcdd7a6d20da156228538f6b3484ae257929b31a6910be95f8d956816895bf659ed4113d425b7dacc94",
      "line": 315,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 22,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, AChE inhibitors that compete for the enzyme site, as succinylcholine, are used as anesthetic adjuvants since these drugs can promote neuromuscular blockage",
      "key": "c85daf6525f1f6ec188260dda035d82718940b5fc754a517bd23a408c624b8caccf979c82e49a668e9413917c0d655a678a217f010296b4c377cbc511239790c",
      "line": 323,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 31,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Choline that is released by ACh hydrolysis in the synaptic cleft is continuously reuptaken into the presynaptic cholinergic neuron by an active transport system (see Fig. 1)",
      "key": "61ce9609a81a778d1266a94dc867943b5eae3e82e11d7d9a23bf637a8a6818ec75e2083e523901ca014c47d9ecb36651e8c5d3889ea2bc6708776ad4a8102bd3",
      "line": 332,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "synaptic cleft",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Cholinergic Neurons",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 133,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Two choline transporters have been identified in neurons: a ubiquitous, low-affinity, sodium-independent transporter that can only be inhibited by high concentrations of hemicholinium-3 (HC-3) (Ki of about 50 Î¼M), and a highaffinity, sodium-dependent, HC-3-sensitive (Ki of 10-100 nM) choline transporter (CHT1)",
      "key": "a5b4b04c26b00b638f593f6b5139f0bb49a05ecd984271c9d0e3ecbead43e00b0c40bf063a60680c7868dacb0f58a5bbaac0fe30db1403e6403e9f824bd15461",
      "line": 342,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "synaptic cleft",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Cholinergic Neurons",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 133,
      "target": 18
    },
    {
      "annotations": {
        "Cell": {
          "cholinergic neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "CHT1 is mainly found in cholinergic neurons [92-94] and is responsible for supplying choline for the synthesis of ACh",
      "key": "9f9bf73f51d0af4963b4ca30875d7fd1271bfe995404bfb8c571d0b99097856ab79fe0471487d9600e95ba54b791dc2e97c087e3ec7ac96c543afc459705cbad",
      "line": 349,
      "relation": "increases",
      "source": 133,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "3d464bd64965765c1634e53598ba4c6f3b29e564447284e6d8b1412819d4241177ab8a8be6f1168f036bbd90d2d316aff3496d85ec40c88d04d15ba7a19b43d9",
      "line": 377,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "synaptic cleft",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Cholinergic Neurons",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 133,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "d36f2d45445cad123dbbc66f650b078f34c01687f28e47769fb9353f1d8181c2491b22be5158ae98ece8c9f85a7a09922ef63239e74cbbf3b6be980bff466838",
      "line": 378,
      "relation": "increases",
      "source": 133,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, mice that display a disruption of CHT1 gene expression exhibit symptoms related to ACh deficit and inevitable death within an hour of birth",
      "key": "f5e6150f76b1d848d3f53430edf65c1b96fa0e9fcf6734337451a397ff03ba65724951d00c4fe4855c6a5ed6e2f06684d5db0aa47bdfeba2e2e00e6ba29c8a1b",
      "line": 359,
      "relation": "decreases",
      "source": 141,
      "target": 155
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, it has been demonstrated that an increase in neuronal firing can lead to an increase in choline uptake and in the synthesis of ACh",
      "key": "e13cb957a6e4969f17ed384222505f1e3d5cd858d5265ee5ca10c34568eff0b14bab1965e89ae0c0fb7d185c990096adea52c827b3e5ca09005bab3d720ad4cc",
      "line": 366,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "intracellular",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 61,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "b3bb5e88a1f01b194e29a66fe5bd86be850a9df2d46fff8a7396ac3a3392a20bbb994e0c9dde11a42a289f5a175e638da35bd8ceda6fad2d46f0dc807fd74ee6",
      "line": 379,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "synaptic cleft",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Cholinergic Neurons",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 61,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, it has been demonstrated that an increase in neuronal firing can lead to an increase in choline uptake and in the synthesis of ACh",
      "key": "767a9906681da353fe79b7d75deda28df18f86ad6b10ab1dcfa7e24a62d7183d8dba3892e17eef6a25a587eaa216691b7afb1bff18c198da9d80025171ccb098",
      "line": 367,
      "relation": "increases",
      "source": 61,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Membranes": true,
          "Synaptic Vesicles": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "72cc0cf3e298166d66facdeddacc6ff9ea53667c8ad9e2b4ebed81a8e1da0322c3063124f49fd027d5371ad4ddce57eb12ea3ab957e1332168a2d4eb58d20268",
      "line": 380,
      "relation": "increases",
      "source": 61,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "cc2aea3fc1cde43ecda64e99b801511ec88f1aee71e6bbadccd12dc971c63a677af7816ab0e3f01e07adc2a1fb298530ab787f124e6b7e2b2b96c293a3540807",
      "line": 385,
      "relation": "association",
      "source": 61,
      "target": 85
    },
    {
      "key": "813c186025ae58007f34955667c0bd3bb1f586537ea2f2913062c25cd9886e554768a21b91e83a6b8114ddd2598f6988952a5a123a8c75a4410bb3e6a6893550",
      "relation": "hasComponent",
      "source": 85,
      "target": 35
    },
    {
      "key": "7855b7cc046bd9dc1349ad4bb54aff8ff4aec0139debe7189f26decc802e4f4f156038b7b2f387578dd9ac42d815e4e188284b3df667b8b025e881be5dda91d2",
      "relation": "hasComponent",
      "source": 85,
      "target": 133
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It is possible that the presence of CHT1 in the membrane of synaptic vesicles and the consequent increase in CHT1 relocation to the plasma membrane following neuronal depolarization could explain why an increase in neuronal firing promotes increased choline reuptake and, thus, ACh synthesis",
      "key": "df30edc1b19423dcae0e9f6cd45281374af5b846de905bd7aa07109533573881825036653423923bf660e0453241a41ad47bfb12cecbf3b2f7cb39d971cbcff4",
      "line": 385,
      "relation": "association",
      "source": 85,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Importantly, the neurons that form the nucleus basalis of Meynert undergo extensive degeneration in AD",
      "key": "cdeb61c443f8e2156718468455cee31baf1e76f2f0d00116d2a036a78de85d7d933ce727c94815f995d1a438615758de5af8bc31a1ee3419a9ed3cb119910aec",
      "line": 392,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 142,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The loss of the nucleus basalis cholinergic neurons in AD patients is severe: from about 500,000 in the healthy adult to less than 100,000 in patients displaying advanced AD",
      "key": "5abdb73f06a887b67dfb0de1b64c1e8108477c4ed4fcd9b1ac9d330a164cb29e41906737f1c6c3811f658ff515580def38df4a050652c7a184f7480dd28b6420",
      "line": 728,
      "relation": "negativeCorrelation",
      "source": 142,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "key": "283b97438ba041fcdbfed79bbd0eed1b89aebb129d532fc6cbc50208a508cb887a0e2108771bfb52793f9eb0b14f09e34855dcb69e5005e90eec9e62d3db71e8",
      "line": 634,
      "relation": "association",
      "source": 142,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "key": "08b48ec6ee3c50a6b9a5eedb92caa7c0f4d752ee6263863984fe5dc36b3f31be0ee5005f53c3aec6a6ca706d68e82a6e9b1e23d038f6838196fd741282127493",
      "line": 656,
      "relation": "positiveCorrelation",
      "source": 142,
      "target": 153
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "key": "fd05772ebb5ab9fa5968c43c536aaafbf2bf95215ae9d210922c4c5e3d15f9a42b2fa61f3cf139e372ce0fc88a02f643b1b5fbfb76245e0ec2670789082e8865",
      "line": 657,
      "relation": "positiveCorrelation",
      "source": 142,
      "target": 157
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "key": "be0d5961edd1e460bcf8dc2d5b3fce495884c3bf40d9d8e741e32ef8aa9991c0682bdd53805fff0b56a588b84116fbd83ae10193ee84faf0ff6142c1f286b209",
      "line": 658,
      "relation": "positiveCorrelation",
      "source": 142,
      "target": 144
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "834e19dbb984d9f4a03eb5f129206e86d7288a70a3402229f2fb39a6f9b5c2d32ab9c620da183a301829a923120d13a2841e78e25e28435a3656fc0a3add2b2e",
      "line": 689,
      "relation": "negativeCorrelation",
      "source": 142,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, it has been demonstrated that ChAT transcription is severely diminished in the remaining cholinergic neurons, which leads to decreased ChAT activity and progression of dementia",
      "key": "34416d5e48ce159b729edfe3b6ad732fff0c49fe494a3a3ddcfaa988fe49f8ccbb5e457ab1b96033a908e459c8c75c8aea1d8bb1dfcf1642dcbef00962f16b11",
      "line": 737,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 142,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Furthermore, some evidences also suggest the involvement of AChE in the pathogenesis of AD",
      "key": "3fca74190972abb8d124e323989477a219356e05b67999ca634a9ae2827836f86d369b2fd67912e8eafc29c0843de7ffb28a2f0072fec3d482489a236034856f",
      "line": 753,
      "relation": "association",
      "source": 142,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Rivastigmine has also been used for AD treatment due to its ease of use (transdermal patch) and good tolerability by patients",
      "key": "96df2747746a6934eddacae5e8d27c7dbef557a1bf6cdf711eb6750876f9b2c7f45fbae0d9e504d4b0a9aaa019c0c57672844ea234d26ce22eb3d328f2418559",
      "line": 820,
      "relation": "negativeCorrelation",
      "source": 142,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that M1 muscarinic receptors coupling to G-proteins is impaired in the neocortex of AD patients and that the extent of M1/G-protein uncoupling is related to the severity of cognitive symptoms in AD",
      "key": "2921d006338a8462ab1ebb20117a056d767c9720132bf5e82c149af900ca6cd7dc9bc286b0d564ab287533c02a6207497509f237affe8fb9fd50acefeba1a5ee",
      "line": 829,
      "relation": "negativeCorrelation",
      "source": 142,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The loss of the nucleus basalis cholinergic neurons in AD patients is severe: from about 500,000 in the healthy adult to less than 100,000 in patients displaying advanced AD",
      "key": "3fde9a104e55d5d687aac53a118de610efbe78cb662620b7da8e230e00b3ee37cfeb1568a54d65bae833bb5b60e4a08695d2f9a8e1edb946942fcdbd869992cb",
      "line": 728,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "key": "0f89e18910f3eeb966e941e655d9dad63428093f68b695b183faeb0fd7f2df89db6d264e7681e65e164f304bfbedd363bab79e6e222f8d0faf18c42c6ae6295e",
      "line": 398,
      "relation": "increases",
      "source": 123,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "key": "ae48a2aa9c9c8d76d817f78e820a7106cccdcf9ddf8a1c554ae552144fac27fd8fec299eea967cbdb8e83037e4975f21b8f836b476c45f90eca78cf781392f67",
      "line": 399,
      "relation": "increases",
      "source": 124,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "key": "e42c99da0b26084ba3d4b6af24dab075f41d17222be75c69498111a01dd23495691da378e4a07e9cd8cc5b974e54616a07af1cadd71108834bc8da270ef076e0",
      "line": 400,
      "relation": "increases",
      "source": 125,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "key": "116e30a6c2bf9482e92b23021a261f5f30187a17b2216633dac604b35f0d0b1d8694283cd0213f5725260e28c957c11186045bab13b2f8a1776ca4011b402861",
      "line": 401,
      "relation": "increases",
      "source": 119,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Nicotinic receptors are formed by five different subunits: Î±, Î², Î´, and Î³ (fetal) or Îµ (adult)",
      "key": "be608a21dcf478f3b219e6085723d05c64007ed08f765598ae7ab4019b004ff726f718ab9d8e7c074682c7d82ef3897e9e20b2350b2200a9808492cf6cf908d2",
      "line": 402,
      "relation": "increases",
      "source": 110,
      "target": 56
    },
    {
      "key": "6dc26bdd2f67a9d4e39fc6b74d80fe9e946525dc0bbd555082ff6a937962e347eab288579a461bf958247e2b39b3fb9edb0b5a020935b05852dec59a7cfb36cd",
      "relation": "hasComponent",
      "source": 93,
      "target": 110
    },
    {
      "key": "21c91b81173c17b8bc9cc7d0094c765bbae2ae4e53c0f8c2b29200f887b167f45619d49afb5edc22a4e374d71cff476f2f37df438a60c56f74b7c8e244ef7504",
      "relation": "hasComponent",
      "source": 93,
      "target": 119
    },
    {
      "key": "8b395a38d2734a5f2ba774096d54138c0a74fd0fc729973f32edb9ea58b6f32c302d970e165676bc1a3c585e9b4cc0ef22e724126ef2e827278737f59cca65c6",
      "relation": "hasComponent",
      "source": 93,
      "target": 123
    },
    {
      "key": "33c4c88e2f1e127d98ebfe2f4271383d794890f607100f4bbb0f1cdb472b4a1b13261cc44456d373291c51e2ec9d0a305e78f538e351aac4a306460d45e2e671",
      "relation": "hasComponent",
      "source": 93,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Ganglia": true,
          "Muscles": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Cholinergic nicotinic receptors expressed in muscle and ganglia are comprised of two Î± subunits plus each of the other three",
      "key": "1159ec12d390ab5abeab307e5960cd6b62770b0e580fa6715f6143fa66721254ae22837dce14c78c1bdb63755517c22e08b722778223b87115a78d9cdfc3c343",
      "line": 410,
      "relation": "increases",
      "source": 93,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "7e20aa00a0f9cd1c5bca204262cec1be91a21c03f858a3f0ee7637112e6a733a38bfd03aed226b679744612693cdd0982a9d175c5c4bce6704c8ff955b02a11d",
      "line": 419,
      "relation": "increases",
      "source": 112,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "9f4e17418591b9e8394d5d003cfcfffa9f941bf17354894bd491929da3da15dd9a4fcd00c7168cc842209be84c65d14f7f3d7ee56ffcecb96e4cfd47d2210b81",
      "line": 420,
      "relation": "increases",
      "source": 113,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "6365655c556be446785db31be7e6b5859bdd4358afbbcce1b20727a8823d190fcf99359673af3e1f4f860508961c8018d289ce780b957dc795ad0c64e46d7f9d",
      "line": 421,
      "relation": "increases",
      "source": 114,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "441e34c236916f02023f3a98ea2ffd6b9a7299559cf45758841ba6efb81d7484d43dcbe9e2881edbb4933b3808cf2bc794b85434b349d005ce7d376562a2df51",
      "line": 422,
      "relation": "increases",
      "source": 115,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "7d34b7bfd6a96abd8321630960fe40f7b20e0c90c2914cf79ea8da99671288dd41eb0cfe459f6b3ee7fabf0126c1a082fc71f381c1d9a6d5f8f75dda81c7644c",
      "line": 423,
      "relation": "increases",
      "source": 116,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "b5808aaab18561044fa95394fb2b9d5e1d8ec279a3f5848977ba67183906b4df145a5dc022516a9517badf1a3442e2cbd53dc6f66f15b62571c58f1c043e03ca",
      "line": 424,
      "relation": "increases",
      "source": 117,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "b37df8ebd8affdffb57753f39dbc0ff1b3132fab25346a44fd2aa9a1c1fb3a9cd0155f5b656c95689eebbe08b9697ba75efa0fb00e91e5b055f0488311a0e052",
      "line": 425,
      "relation": "increases",
      "source": 118,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "7e9a8f7d3354576f0e33b5d893a48aece14548e980987b04da17c4daa2672e8d02cc5c72cce70c33b1eb9d6669d1b01c8faf9e13c48004218d3102794040a22b",
      "line": 426,
      "relation": "increases",
      "source": 111,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "dfb2832f2af68f46673717c2a7e81fb0d9393bf66f099ca97036394b82d3df23d193a9e6e2d756e76af37ec1a78c87dae5a100957e44715d41ac52c215505d67",
      "line": 427,
      "relation": "increases",
      "source": 120,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "f4456605a7472367cb198b26a0e32e879b549875c3d18b7ae5d34ec5239ad60f590e99840336454cd2084de2725051d967f830d1e7653390322e7fd905d4e253",
      "line": 428,
      "relation": "increases",
      "source": 121,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, neuronal nicotinic receptors are formed by the combination of only two types of subunits (Î±2-10 and Î²2-4)",
      "key": "42115dc7a80281950b68ebe0ef733c4f1861d2eb94d56f58375cc70c2bf867c6157fca27d54a46f470374ea661f24e85b0813951d91b9a6475cb2c488cee10d1",
      "line": 429,
      "relation": "increases",
      "source": 122,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "key": "3424b8d80197a407e7d14a088d431ddf81d7539d1a185f6419e594a94b4cf27087b579d6caa3359909f7afd6289dfedbdd713dac1aff581296247d063edaac10",
      "line": 718,
      "relation": "association",
      "source": 80,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "8f4ebb6527141747f2918150c436381ca076a31a5819ef2bfcdacbe5219ef546dc3661fdd6e238fdabcbe3150b4f368324d9c9d1cd5e5a2605a05a203441b4db",
      "line": 461,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "d793148cfe4efb23f7ab46db013d22742a7a8cc1989335cf88e06c3287a84d845eb4df783345e4be2a8aee510a4e86ff05b6228fa08aa08f70305d2a1075fa7a",
      "line": 462,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "a28586547264c55114a7fd6c698459c988571ce82e59372f2af89ffc868fd7ddf3b4a74158e6544afaac11c6aa2ee8a76d7fa63124df7f7ec2a4bfda7b0f31ab",
      "line": 463,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "92318cf8f5ed71441b7c922656ca4cf83801ab8810e06d3eba8553a37c7e877c61ce0bba38447c4239cb028a2fd703828c1d81a2463241aa913c55ed5e388b28",
      "line": 464,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "503786c42badadb5a9bc41029a3d92cff87308a737fd5fdf2ed1108d11b363692903b20accb90cc487d7c7c64dbf280320c0d5cf40a1a3788db015e25d282385",
      "line": 465,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Synapses": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of nicotinic receptors present at the CNS presynaptic neuronal membrane leads to an increase in presynaptic Ca2+ concentration, which may facilitate the release of a number of neurotransmitters, such as glutamate, GABA, dopamine, serotonin, norepinephrine, as well as ACh",
      "key": "2782566e51a3d72cee60024da9e8342d4ad8ae91fd29bdc46f45ba35d8aa75535ac6aa89c228aaf8fda4693690ab4a0fb60f25f501e6d1902b5f6aaeede77855",
      "line": 466,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover,nicotinic receptors can also be regulated allosterically by Ca2+",
      "key": "a186553f90925c5cc564389c7ab8d6e0a375ab8dad2c679681c36ac3527aea09ee11d6e1107294a260e599dea12294a73e59141f3a8e96b575aeda153d341b9c",
      "line": 518,
      "relation": "regulates",
      "source": 7,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "f2693492e132fae0a3c1c4e5a2157212b2d9ded0900ba3844e6cff8d06d9919518f90afec2d24d494eb5c56294c4e8d0b79cfd634066173a59c2296c02c054a6",
      "line": 499,
      "relation": "association",
      "source": 74,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the interaction of the cholinergic and glutamatergic systems seems to be important not only for cognitive processes but also for neuroprotection, as it has been shown that nicotinic receptors agonists are neuroprotective in a mechanism that is Ca2+-dependent and that involves the glutamatergic system",
      "key": "a3ba4e92c95992096f478a383f7117c4aa09cbe15621c3cf97f01c6573c72da2b420892f26b637fa2dc791ec7c91c9d2ec938dd2439afa0dc7f117cf63a4370f",
      "line": 500,
      "relation": "association",
      "source": 74,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "key": "72942728fed1dcfe9786d407ed86495af0fd332bec7747ae7be4b784db98388109f855a474246c5c444c6e3709f721577d4cea41af82ec8b84385193f837c7d6",
      "line": 510,
      "relation": "increases",
      "source": 98,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "key": "475b31aa5fa305fa901657e249d764980fcb938cbad73b5f5acbf68aae596be9a196bb31c6c3dda3f5e72e116d6b572a31ed5e1d16d232a9acaba9b8bb53613a",
      "line": 513,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 97,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that phosphorylation of nicotinic receptors by protein kinase A, protein kinase C, and tyrosine kinase can regulate receptor activity",
      "key": "1e031e07f898b22aa128ab7c12506b0b9379441e4f49768360e98b9e4079430088745f8fa27a44653b812a8af8ad60453ff125e1e37026781dc5b9e84320fb1b",
      "line": 512,
      "relation": "increases",
      "source": 51,
      "target": 97
    },
    {
      "key": "d0a8bd534786aa309d6328c4b83efa961f4f1811a8ccd5dac3dd1bd1ab5108683d9f8561e4c7bc6dfce02b8e3dd1836d90c12c73a3770132a512143db642713e",
      "relation": "hasComponent",
      "source": 81,
      "target": 0
    },
    {
      "key": "ddb07d2d01b72827655942f435a33cc157410c315f88f3e59f6d163d11f4e423a9d4462e87df7e588b5dc8442e1610915bca88a704a609c95ab2a800936544fd",
      "relation": "hasComponent",
      "source": 81,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Not only nicotine, but also DMPP (1,1-Dimethyl-4- phenylpiperazinium) and cystine can act as nicotinic receptor agonists",
      "key": "62b9394571c92be319d566c7e25917a99fe3a6678a9168eef841c3ae5df0b0fe34e3a3b49ad731ebf0c1b95c463c0b2c94e89e5ea151376b354a7dd520187156",
      "line": 524,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 81,
      "target": 96
    },
    {
      "key": "7aa63192d1dad3f5201d75d55ef0a7dcc916207b01b3805d17f814281ffe4596fbb50bd283d8a117f896b8367b8bb2791df2ac9f5864ec84e81a7c2474ae3497",
      "relation": "hasComponent",
      "source": 83,
      "target": 19
    },
    {
      "key": "66ea126c89026a891d5a936644f53aebc5dc1200c59334acc593c076e0004086dc54503be46f0f97f0270d6198978b6827373cff3664cb312a4e36f7d3762f9e",
      "relation": "hasComponent",
      "source": 83,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Not only nicotine, but also DMPP (1,1-Dimethyl-4- phenylpiperazinium) and cystine can act as nicotinic receptor agonists",
      "key": "d880bd4cb412c6573112b97bbb2998ab4b13fb3bd6eb9c6b148a9262b3bd0076082d0069566d52ab442b699285257d4ac4efc1df9fd4437256e88c3670a316b8",
      "line": 525,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 83,
      "target": 96
    },
    {
      "key": "4145f82bce1562f0e44acefd4c607265879e345771c4f14d44a36db979ad42f20c8b3c569051823d83a397794b823e6040a982a25b09d87ebaac9d73a120d1bb",
      "relation": "hasComponent",
      "source": 84,
      "target": 26
    },
    {
      "key": "3069ebcfcb2409924fd49c3ea4ee7f506d68e231cf68bdbbb328b98148d959af12e844de219b438e7355508bc6d19bcd83c8f911248cc1b3b93a140f6461ad46",
      "relation": "hasComponent",
      "source": 84,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Not only nicotine, but also DMPP (1,1-Dimethyl-4- phenylpiperazinium) and cystine can act as nicotinic receptor agonists",
      "key": "572b8c65d836a1eb74acd6d54d07c5565fb9ecdb177b304e474cf0ba9870be9f3825656fe2b2e799943bfebcfadd6b78e40ef4a247aecc91e9b72cb99858b74d",
      "line": 526,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 84,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Curare is the best known antagonist for nicotinic receptors, although this drug is not capable of blocking central nicotinic receptors",
      "key": "94bda8808d5736e88442abf2376e50c1ecada9bb99c06d94cd49e0efa4fd9f118d03437d8411e1ed2c8aa0007905869b0a0bda1242b7509be94695316df910c7",
      "line": 533,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 32,
      "target": 96
    },
    {
      "key": "97aec1822463db3df8761ed1833bd9b8c631bd69133a32cf0f05edb098cfc5add0c52e90dcec211fcf0323bdc10fb7767dfb8bc4499755844cc51d760b5aff3c",
      "relation": "hasComponent",
      "source": 88,
      "target": 105
    },
    {
      "key": "9fab2db717335943361c94021d48aea22a3ca902c3e31e7041bc9c831ac57199d581f32c9c9e9d7e2f1f58428105288eb936c6c9c8dc9559eea31cf074358fea",
      "relation": "hasComponent",
      "source": 88,
      "target": 136
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "c2c7d421ffed0fbfa8f0a5d495853f836c0b5a4bdc31a854e982559bf9bb3be87d641d3c5ac4286f7031777626ee1a879b0893390eafec2b33b894386e49bba5",
      "line": 557,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 88,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "0549b4e5a9f0b597120a1d96744d3d0092377b29dca6def4d764260a3abde9911126f95cbdbd03e4da92fbf94c0ef34a90658585dd6236cb055e2d2b7c55666b",
      "line": 558,
      "relation": "increases",
      "source": 88,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "56e2c32521eff4a83ec348b241673663ddebbe244f022c87e104d05e965944f966c32c57381644649f5e2070ccfe08223a9e5c3cf3ad12d4023e150bf50b5964",
      "line": 559,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 88,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, stimulation of GÎ±q coupled muscarinic receptors generates intracellular second messengers that can facilitate N-methyl-D-aspartate (NMDA) currents",
      "key": "1356494936d6a1a8af911cb85e9a5be646212c6a09c92f1936c9dfce116a33ab41607a913e6694eeb5bfc5bbaad1e829c60611c54022e1b9ebc10a5ecdfa116b",
      "line": 609,
      "relation": "increases",
      "source": 88,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that M1 muscarinic receptors coupling to G-proteins is impaired in the neocortex of AD patients and that the extent of M1/G-protein uncoupling is related to the severity of cognitive symptoms in AD",
      "key": "3ca5f507a20b7ff63b9e6777882070980f0586ceaea6cff2332165ae7c5c039c62c158f79e650e3dd6982d4806807b447634b17ed7cdef6e9e3f7b6fb9fbec67",
      "line": 829,
      "relation": "negativeCorrelation",
      "source": 88,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that M1 muscarinic receptors coupling to G-proteins is impaired in the neocortex of AD patients and that the extent of M1/G-protein uncoupling is related to the severity of cognitive symptoms in AD",
      "key": "3208bae3bda72db91decaf76440e73fe46480b06e709e6fe7dd0e4bf82fe5d4578a619c26b7915baaf8447edeb8ec206ab224b636c69a9e7de5ec29d6637ab7d",
      "line": 830,
      "relation": "increases",
      "source": 88,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "65013de5b2e380c1ec816482f4d49cd1585df145b243e3e1730576473116eceac6240450a104b625827af63afcfb6756fc5fb1ca4bfbdd284ff6db2c27d493bd",
      "line": 837,
      "relation": "association",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "0d698a7d0abfdaa778ffe663c10d9fed8c5de7a073acd7ac65c361721c5b203eda6297a3effd46b95dfac8111da009e42a2d165613294158f84634c7f5b866fb",
      "line": 838,
      "relation": "association",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 144
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "79f9c68e3627a45895f8b9f72a3751b9cd45f12489325e7c53d3e5d891cf1e2e7c450a40790df6b030ae45e717dd6a8256ec2af8122fa03f3f23721cba7ad58d",
      "line": 839,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 127
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "f7c02317cca1268515c1fae9e39e02fd968a14016c7f10804896cb36a1eb03f5102f4bfe3ab57fcc90f867b1e7699d1253937d06a0723b0f8a9c5b6a437a9d99",
      "line": 840,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3Î²",
      "key": "21ef9f1ceb29b2806f5be3d649b498e4d4dc348917014b3313b5b43179902fb788e2f3712f58916199f2203ab74e0e27712d135d35a6cf40d871915ef1fca878",
      "line": 847,
      "relation": "decreases",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 128
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3Î²",
      "key": "89e297a2111b302bf6a324170c777d52a8181e1223077f3b996681255f4fe97c9b2c69c7bb3676677579570dcae1eb8aefb3635913fb29479483051cf2348fae",
      "line": 848,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been shown that activation of M1 receptors decreases tau hyperphosphorylation via activation of PKC and inhibition of GSK-3Î²",
      "key": "b98d8560a6db3d13c52ddec924fcfc6b7ca5514120f0251eca440a5cb22d9dae8f3b41fc8d6988f9e7ebf774058b6961b9942414878fdd54a863791ac37b331e",
      "line": 849,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 105,
      "subject": {
        "modifier": "Activity"
      },
      "target": 126
    },
    {
      "key": "ac70342e3d15f9d1b4368aef3db87782824b1750ee60efc56f9ee8bcb68f1a19b2c7845ac65d092dfb330ccdc04703ee88d8269726bf50c6785b0165cc341a7c",
      "relation": "hasComponent",
      "source": 90,
      "target": 107
    },
    {
      "key": "e1bc7804311301c3c9c666ab62f00e9a2d79df7b1d6f039945648bc0ebfb972f51a53e5457223a6875b7d00b5d2650c006f85ecca5d75cb0fe0c30e5d67d99f3",
      "relation": "hasComponent",
      "source": 90,
      "target": 136
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "d09f327f7f3bba01f15eab826e514965e019b369a7c003b8cfba4110f33ea632fe77f151278115b2c79ab10330c5a67229bceeba89487f666c82a5f3e316783b",
      "line": 560,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 90,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "28353130be8d24a53ff43fb44de309459d7fe6d7bc6dc13cc7b2ed13eef3dc5821d3cbc68f236f957840585b167cec5b438f5c045ea6354726e3b481236fd56f",
      "line": 561,
      "relation": "increases",
      "source": 90,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "962f82932a4aa2b9af732c4982b54d5d73c2af208f68154a47f388799d0cfdcfc16208812c1f0c6f44863bbf2e73586f8ca192c7c1126e876a6cd414782591fa",
      "line": 562,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 90,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, stimulation of GÎ±q coupled muscarinic receptors generates intracellular second messengers that can facilitate N-methyl-D-aspartate (NMDA) currents",
      "key": "ed60eedf1bb33270beae41567fda430bc2d41f195fb519dd6803257fdf36b082e551f974cdf1d52a6ccda58e0ce1b184d97a7b78761d6b52601e2d3f405f8d2f",
      "line": 610,
      "relation": "increases",
      "source": 90,
      "target": 55
    },
    {
      "key": "f404a7f80d09e9bee99af36e69524f216ad1db55bf350342bf06e9def8abfffecb286759ad144201fc1d24103633d22226911e2174a080ca86e6fe9e02c94a12",
      "relation": "hasComponent",
      "source": 92,
      "target": 109
    },
    {
      "key": "fbf64303e151f8df377a74016d0fbd5a48822a885dfa67a7f90357d76a6c27cc3a5ebfdd784a2d6da54c52c83779de8f372e81867ec3fade23bdf61f6c413478",
      "relation": "hasComponent",
      "source": 92,
      "target": 136
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "93c36c207139662493c0c6678dcb84e428a02a1d5c666c60b9a94552d3b838fee3109d6ac03cdd18371296707440ca4d95999ef094e456854bf68f10d46d964d",
      "line": 563,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 92,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "cc1fbbd37dba0e20ba262f697b1783f00c92cc4d8745599d7be36d08791d59032c8255871fb46f0276ab3dbc79524ac485c4b825edc3f3cb801cf5d7fd891844",
      "line": 564,
      "relation": "increases",
      "source": 92,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Stimulation of GÎ±q coupled muscarinic receptors leads to activation of phospholipase C and formation of inositol phosphates and other second messengers, which can promote closure of K+ channels, thus facilitating cell excitability",
      "key": "9b3553eafc30ef1c779685fce07c35c78d25374dda36d6755bb6fab31938244e453b47490d42290722a874b4d895d009c0a122988d669780547e90c43a655205",
      "line": 565,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 92,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "On the other hand, stimulation of GÎ±q coupled muscarinic receptors generates intracellular second messengers that can facilitate N-methyl-D-aspartate (NMDA) currents",
      "key": "a09ec9aaa81b5ed3466ea27f51afe56e9fdb0062f785a8a501d262c63b85074831f1914651ff5c7c17e4e55e56bc1de27e783c4ee98b00664f65569778ac7220",
      "line": 611,
      "relation": "increases",
      "source": 92,
      "target": 55
    },
    {
      "key": "01c8dd105642a65571a874aa22d002973e2f2a9064d07c508ca2f81fad2c80d74e797638e8dc6535649aa211f480affe11cd2025332ea511d4af267fa3755649",
      "relation": "hasComponent",
      "source": 89,
      "target": 106
    },
    {
      "key": "263fbda0c435956ca7de8ffff3ad581e15a120cfbe9978f82895aa5189e68893ab8fdf2cbf93cc98a89497725f7f34ecc166258a8a5e7df8c9e77abdf2f9cdea",
      "relation": "hasComponent",
      "source": 89,
      "target": 135
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "key": "28f0db5970cf501a15bd3b1496458d38cff44417df4bbf3e83ed89fc9c003cb9992e158afb2d416d6554a22200ce6b4e9168eae2f0f3f0649425ea763fdf093e",
      "line": 574,
      "relation": "decreases",
      "source": 89,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "key": "cc34c97a8a1ef5520b2f9d65fecee13ac3b1470d8303e342b0481963ded34d476765c1672096369ba50d815a81f9981db11482c009f1ebd6e0272d1dc469f402",
      "line": 575,
      "relation": "decreases",
      "source": 89,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "key": "81d6b94d033ec4996e2cfa65ac33fa02f709f90603c0a2989fab4c82b1bcd2f9e35303dacf675895e1fe2895b9d64b15c236e8839181eb73fdab52d97a349826",
      "line": 576,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 89,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "key": "ec10d285d10dd0d34e566757aedf1936ce17a13a21407db6afc3dbbb82f49bf5552a92a5dc7d5cfc45e303b699592a561c02584faa847fdb37ed7a8d34303fcb",
      "line": 876,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 106,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition, activation of M2 receptors can cause an increase in AÎ² production",
      "key": "88edf2f4373d98a531eea62d5dda99685af9bb39143b8bb5ca46d9433ebe7070360715a0b552ece377d8e26f906c6de485d8e9a51baf8d9c13579ae12008161a",
      "line": 884,
      "relation": "increases",
      "source": 106,
      "subject": {
        "modifier": "Activity"
      },
      "target": 6
    },
    {
      "key": "a3a9fdd8bc192b096fe065de0d8884089942becdce92c054f10e00a398d335f2fa498e685ed0af643c880ef2415fa6b6468cb7c4328966292c71ab0502b48b2d",
      "relation": "hasComponent",
      "source": 91,
      "target": 108
    },
    {
      "key": "49d099d9d0937f5db2960557ba75ae484fd6237c92ad9fc0c374c558d87e89994911f2dc7241ffce14550cf2cb149c5bcb4fcedc76315e773f3385e3bdd1e0dd",
      "relation": "hasComponent",
      "source": 91,
      "target": 135
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "key": "49a13d75b41a3124c230faf5ed073598883b4d6105ddc34eff84812fcce076a2926fefa631b0892ddadf706f11d9219d5148a2bbe6cd35a38cf19fe4559b9b23",
      "line": 577,
      "relation": "decreases",
      "source": 91,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "key": "5aa2a60b5b724018b0134f0b6989ef7db6b1176213e8d08cb62c07caf4906fa1d5ac04dc5ae76db15fa2ba0f3034ce8906a98735988e4df9842c3e16acb26296",
      "line": 578,
      "relation": "decreases",
      "source": 91,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Activation of GÎ±i coupled muscarinic receptors leads to inhibition of adenylyl cyclase and reduction of cyclic adenosine monophosphate (cAMP) levels, promoting inhibition of voltage-gated Ca2+ channels and, thus, diminishing cell excitability",
      "key": "896b03272ae82f5bcaaeef53534453694ccee88d8a8d8fab494bd124741ef9f5a72993d2d38cf14724aae19678e65658df83beb4b1800345c9554b585ac533da",
      "line": 579,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 91,
      "target": 43
    },
    {
      "key": "9a942090a9790fab339140bdb1fd188e73f9ed5fb64a8b73f2f9a550817c4ffb8afaf93b3a359342417f8167daaff4c412d8f8c618a40f3b43806fb468f56779",
      "relation": "hasComponent",
      "source": 82,
      "target": 13
    },
    {
      "key": "7c57ea112c88c4fe018864dfcf69a5e595fa7ef0032dd54a6f0c01108703b7eb28f860e4e2723ee8dd25a7c3cdf17d73aa0a50367954dd0d98aaf38084682241",
      "relation": "hasComponent",
      "source": 82,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The first selective agonist identified for muscarinic receptors was muscarine and, so far, there is no agonist available with a specific selectivity for one particular subtype of muscarinic receptor",
      "key": "7768800aa4ecb10b4aaecc93e380fb9786cb7dab0a146ffa56d0f6a756e3f019cfd48093effc14d2c279d65df1cb1fcc5de59540ac1f14eed79c565a6e60e42b",
      "line": 619,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 82,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The two best known muscarinic receptor antagonists are atropine and quinuclidinyl benzilate, which block all muscarinic receptors",
      "key": "9d087c69eff331dd352ccee635f48562ba0a85f15ba10cc1293a5301ec0b9e2369c54a1fbd8a5bc8d95d2eae0a37b9934e06e6e5afa5f60fef19f4ea9b7ba118",
      "line": 626,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 17,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "The two best known muscarinic receptor antagonists are atropine and quinuclidinyl benzilate, which block all muscarinic receptors",
      "key": "4f5e54143d351961239d1929eb8f8def3563597a1e35239c465e88a2c40c068f2d5f26991fbbffa0e6691da162dd23b2ad839cefa4fbad7505e5c7b514e4a3b0",
      "line": 627,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 52,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Because ACh has an important role in cognitive processes, the cholinergic system is pointed as an important factor in many forms of dementia, including AD",
      "key": "63eeab21058e1b49be29cbffaa3a78430bfba8a7438839cf988b2430deb98214542f103864bdc9b2e24fec84b2b3ff7eb98d221254e4a49f8a33e93a8b994998",
      "line": 635,
      "relation": "association",
      "source": 156,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, it has been shown that blocking CA3 cholinergic receptors impairs the encoding of information and memory",
      "key": "af3c28c11dc046ebeaa8c00e1087813e6ded619e2803f9e22e74f685587d203f5b9eb47c088e803177e88f077abac11a931513add91d7a1247c3b0e9a80f7265",
      "line": 650,
      "relation": "increases",
      "source": 53,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "key": "3396a2dbb5b7c477621146435333b26a685b94769810e119a88ea10a096e7476b6b8b1a543e93cea7b9713460595f8610b7f2748d797fc711dca8ff6f0b76e8e",
      "line": 656,
      "relation": "positiveCorrelation",
      "source": 153,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "key": "c8df4876897d747014944c927079cea6c6b390eb8620fb5519f86201cfdca06754cf5fde9a567d8fb3ffdeb2228597cf606613caf0fd9204f7beec02a6911f0a",
      "line": 657,
      "relation": "positiveCorrelation",
      "source": 157,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition to cognitive alterations, psychiatric symptoms are frequently observed in AD patients, including apathy and depression",
      "key": "385a5bdca414840046642b9f421a0d922305f9cdb20b62fbcd327e987a003ac1542486397db78f5fca9eafb91e28fe3e3ca45e7779679434baab154a822af6b2",
      "line": 658,
      "relation": "positiveCorrelation",
      "source": 144,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "key": "2ab634dcbcc697456df0e2c4d4f9e4c8a5b6ca2c9617c3cdedd182e8d297aa91f7e2bc913ef57bce2c1a480b124941b265c51b127414af13212a2a842b10edd6",
      "line": 709,
      "relation": "negativeCorrelation",
      "source": 144,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "303234c290495a5e73ff8fd8c7250af3552cabed4e36dec50331ba19166c9c61600461ce1528572801b0763cd3bc87bf7e402dbdf40f153e3432595e1389cbb4",
      "line": 838,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 144,
      "target": 105
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Corroborating this hypothesis, it has been demonstrated that dopamine efflux is increased in the nucleus accumbens of M4 knockout mice",
      "key": "e274cc26f70c733d481eaf8be1dd777952aa5383e11d742e046a55cf9d74752e079e80df363de7447c1bf07d586ad3aefde3fc8461dd859ac9dff48507f3d36f",
      "line": 677,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 139,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "3fd8fbd11c54918aaffa81535d664cfccb97c8478da816eb3c065650851661bae233dfb0024342b7118e8d4e98a2eb81f6563f9ed80cc98709baf22e39715351",
      "line": 690,
      "relation": "negativeCorrelation",
      "source": 150,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "5472847c13c07155e1f36fcef5de5a177a0e13c7ea00704386e98089f7271424d85446e2f132175fc0f8ee7d8d174a054f2c44e7486ee11e45c5b56221b1c11f",
      "line": 691,
      "relation": "negativeCorrelation",
      "source": 145,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "27fa1c53294a341db24ab01e4e9706ce4c90675364b6f5c21c7543de682deab3357d27af749ed899a8b2375cf1db964692c9c4701f25c72f3f76128b92ef2a94",
      "line": 692,
      "relation": "negativeCorrelation",
      "source": 143,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "5816a7231a23b0110c775fa10a31f9242e3be0d0b1945aa9d4f5c4474a4a7effb598cd9eb7e22f421bf01343980fa6a7d8fce4e550f709e99196ea3048d1e293",
      "line": 693,
      "relation": "negativeCorrelation",
      "source": 152,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true,
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Further highlighting the importance of the cholinergic system in the CNS, cholinergic neuronal loss, especially in the basal forebrain, occurs not only in AD, but also in Parkinsonâs disease [190, 191], Down syndrome [192], amyotrophic lateral sclerosis [193, 194], progressive supranuclear palsy [195, 196], and olivopontocerebellar atrophy [197]",
      "key": "39bcdc07c13ad750ff74f67d5d067c1d2ff7388e9b21ef19d5d6bc5e593ae01f10c3a77e0abfbe99c1096597f6b926b96387c5de2a57c17d2df872c04ce57ef1",
      "line": 694,
      "relation": "negativeCorrelation",
      "source": 149,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, Huntingtonâs disease appears to be associated with decreased ChAT activity",
      "key": "916d2adfe3ff9c2da14934d7a4264992ba62b7b6692c6a200e72e5ecad2fbbf99de80f7b53ec5d8b48268a8dc445e3545492d2595c88657a5dd01af253f46bac",
      "line": 700,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 146,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "key": "f0c98ae581e4f6bb0c70718a2a5bdf7e7ad974945ee638f00e5b674abc979ff2287a4b5703c818a014053c2b5846ab656e70997530c2511d1636b2af34b7a422",
      "line": 708,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 38,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "key": "deba40c70a6af2288afca82041dced9ea93c374c00f459c2aeaf0a438550fc72ed2093906cf2df00c28e913c624538b0dc679946ae0e093f0c5d38c540f6c637",
      "line": 708,
      "relation": "association",
      "source": 34,
      "subject": {
        "modifier": "Activity"
      },
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that cholinergic synapses are particularly affected by AÎ² oligomers early neurotoxicity [218, 219] and that synaptic loss is the major correlate of cognitive impairment",
      "key": "dd46448ba4954932a48b53895805e69cf132af5c85574537be7252d2e298d4e31fa1f40c70790988f7716472ba83261b99cc535d4a159e371acb25cdc6d90c76",
      "line": 709,
      "relation": "negativeCorrelation",
      "source": 36,
      "target": 144
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In fact, the memory deficit and neuropathology severity observed in patients exhibiting AD highly correlate with changes in hippocampal synaptic transmission, especially with changes in synaptophysin expression, a presynaptic vesicle protein",
      "key": "634f2dc27c53b20f25027ea24c17fab7c8b9fcf38c4f4e516f4b3c1d7dfb7faa56e0cb85bf5bd0d1b1fad895cb518a08d5b51ceeee44be19ec3f0e4c50e1c793",
      "line": 719,
      "relation": "association",
      "source": 134,
      "target": 77
    },
    {
      "key": "b0e3226e03b86685b6e45c50118341a1be7ab025ec57a7b60f282a0abf6c44e0d9ecddc01be14cddd87325404421125c3359c7f4f1fba188d5217c1cce6a470f",
      "relation": "hasComponent",
      "source": 86,
      "target": 41
    },
    {
      "key": "e8b7fbcb84a392cae8d385c4db6d1feb8e220c8711f93c267ebba69af73ac043c72493b60157e75ffd36139cb5ccee48a500ff8f2881efb679db09370cb2b8ed",
      "relation": "hasComponent",
      "source": 86,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "A molecular modeling study showed that AChE interacts with the AÎ² peptide and promotes amyloid fibril formation",
      "key": "dca611d2a484ce664ab031991b48ec9786368536df730f119c904e3eb4f8755ba98943dbb362ec6a8e17f503980d3c2566f09dd07ce2498864d24e017642d476",
      "line": 759,
      "relation": "increases",
      "source": 86,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In this work, kinetic analyses revealed that a structural motif in AChE (a hydrophobic sequence of 35 resides peptides) was able to promote amyloid formation and its incorporation into the growing AÎ²-fibrils",
      "key": "b4997b170cb5d0ed2e26729960218b69fe00959baf14ac2b823bff131af2e4859f7dceceb3177b30ea49ca9b443d59e591e32ad9ad98795e7a290ef8af576905",
      "line": 767,
      "relation": "increases",
      "source": 6,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "ee1f55c135d92099a0ec0910faf950207c97dcbe8dbec37522b7efc9c6e975ebc8e1f9209e168e0eaa861d7e19942401fe9ba9fa4bd349a1d171aaf177c33bc0",
      "line": 840,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 6,
      "subject": {
        "modifier": "Activity"
      },
      "target": 105
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "However, further studies have demonstrated that nicotinic receptor activation can lead to an increase in AÎ²-mediated tau phosphorylation",
      "key": "cf59c400bbac3d4faec345393d5367df28327b7633bb637cdbcb8aeb6989f2e5db4d64ebdac8ab79d42fd648d05f086bf47a57cc663991f1b0152020de491827",
      "line": 892,
      "relation": "regulates",
      "source": 6,
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition, quantitative autoradiography assay revealed that choline uptake was reduced in the hippocampus of these animals and that the expression of muscarinic and nicotinic cholinergic receptors was diminished",
      "key": "54a98043d1db18d6369d8b9b0926288fc8c975e591d8d8add79225cfed2d6c4a6e2c90c635089b13fcadcabdec5f4a79a6db8f0504b8deecdd6682ca86f40244",
      "line": 778,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "intracellular",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 138,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition, quantitative autoradiography assay revealed that choline uptake was reduced in the hippocampus of these animals and that the expression of muscarinic and nicotinic cholinergic receptors was diminished",
      "key": "59bd0f653a54a74fbb1ba6dca74ee67c019d92e0f8219ea6bf5f94cea24a8c0d306e179ace65b133e5c73b6949fa5f86893f356d903ea8a0a010530cb23ed29e",
      "line": 779,
      "relation": "decreases",
      "source": 138,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In addition, quantitative autoradiography assay revealed that choline uptake was reduced in the hippocampus of these animals and that the expression of muscarinic and nicotinic cholinergic receptors was diminished",
      "key": "7fa89e94eb87e7f2268fbd0e3eda9b650a13acdb134b0469dd9ecd07b569081c4b77c33053daae89c8c3be4c4c7cd172a0960cab40f3dfa798f0359fa3d03539",
      "line": 780,
      "relation": "decreases",
      "source": 138,
      "target": 96
    },
    {
      "key": "92ab82e51e25478c59ada31ae634e8dc5fa97aac5fcf141761af663f78d6c7606531d40ca010d5a522e81d0df6a8e8643c6649a235381911a8d0ef877041dcfe",
      "relation": "hasVariant",
      "source": 137,
      "target": 138
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Cholinesterase inhibitors can increase ACh levels in the synaptic cleft and partially ameliorate cognitive symptoms, enhance quality of life and diminish caregiver burden for patients with mild to severe AD",
      "key": "453feafd07cd36fe733d16930667558dda84286534133460fec5da2028ad98844f85ea73cee14c85ac9abe472411cc1a05395a706a3b57d01b1bb4cf573e16b0",
      "line": 794,
      "relation": "increases",
      "source": 46,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Cholinesterase inhibitors can increase ACh levels in the synaptic cleft and partially ameliorate cognitive symptoms, enhance quality of life and diminish caregiver burden for patients with mild to severe AD",
      "key": "d84795d44f5177f183ff973056c4d5a460d3471ee52ac8781810687e9c571f79fc71c2400ecd8c4313d8aab6a505de1f37f4e7682e3cb9dce3c1ffb5ec507626",
      "line": 795,
      "relation": "increases",
      "source": 46,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "It has been demonstrated that treatment with donepezil is associated with significant cognitive and functional benefits over the course of 12 months in patients with moderate to severe AD",
      "key": "93fa6d94e55cc6427880347ca458e21980d19e3f67d519f711ea213da49da1e67a7f59798ca149b3a048a85b4397c4227f5dfd1dd6fbafc2a6a19e7ec5175082",
      "line": 803,
      "relation": "increases",
      "source": 20,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a double-blind study designed to assess patients survival with mild to moderately severe AD, the long-term treatment (2 years) with galantamine significantly reduced mortality and cognition decline, besides improving daily live activities in mild to moderate AD patients",
      "key": "56a54e2804970dd274607ab54db136493a211baacf38e0c98869cbad4414d88f86f556165ac6b0bea73776724cab733088c4c066844c98eeb7059f453779a361",
      "line": 812,
      "relation": "decreases",
      "source": 23,
      "target": 155
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a double-blind study designed to assess patients survival with mild to moderately severe AD, the long-term treatment (2 years) with galantamine significantly reduced mortality and cognition decline, besides improving daily live activities in mild to moderate AD patients",
      "key": "3c9e66911ca43938cd65b007dff1b88432220ca186debaa511c70392a3463b985edea297749bc65ce2be13894cda79c8cfb012167362e76a0da66b07388acc5a",
      "line": 813,
      "relation": "increases",
      "source": 23,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Rivastigmine has also been used for AD treatment due to its ease of use (transdermal patch) and good tolerability by patients",
      "key": "62ae10d9ce1e6c2ea20b30ff72c55031db8aad02a152c8bb6ef75ce9d71c02c22deb769fb94b44388c6f851d761c93aecd142f368c4c92d59db953f4549a69f4",
      "line": 820,
      "relation": "negativeCorrelation",
      "source": 29,
      "target": 142
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Interestingly, M1 receptor signaling affects several of AD major hallmarks, including cholinergic deficit, cognitive dysfunction, and tau and AÎ² pathologies",
      "key": "1e4acfd8a5460eeec91f4d75f151774e2b0367012824b45b0171b44676f829210b815a8f07904e326a4c664feffc07765854420a6dccf50173354d80d2c54760",
      "line": 839,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 127,
      "subject": {
        "modifier": "Activity"
      },
      "target": 105
    },
    {
      "key": "9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2",
      "relation": "hasVariant",
      "source": 127,
      "target": 128
    },
    {
      "key": "1f9bd7c2867036707fe963649511c37811b9c55d8f86d32aaf19a2b9ae43692126867debd9355b90aee88e793e854340f6276fe41c9492d1abb3c766f366e2e5",
      "relation": "hasVariant",
      "source": 127,
      "target": 130
    },
    {
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48",
      "relation": "hasVariant",
      "source": 127,
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "key": "20a5f102e1aeb46a749e279efe638bbb00c7b2de66e5da1f544a1894b372293a92082aed32de47188c59d405e69270e4de47a81c2103ea4c6909a1b6b28ed0e1",
      "line": 857,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 58,
      "target": 105
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "key": "85b243b5d5e3121551333aa080f296485fff65072da64cbc08950b4619bff86dd811097dfe25404d1670cc1ab9658f978b282d4f37090693e87c05d71a6b5299",
      "line": 858,
      "relation": "increases",
      "source": 58,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "key": "9a675c4d31d862536b1dce92c901229b11729f126dadde1c93dadcb641346edb12adc36ca646f954f79bcfdbd02a352ed075ffde92c8b4327cb28d0b88a6106a",
      "line": 859,
      "relation": "decreases",
      "source": 58,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neocortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the M1 agonist AF267B can rescue the cognitive impairment and decrease AÎ²42 and tau abnormalities in the cortex and hippocampus of a mouse model of AD",
      "key": "8b62d988af75e908d997373273aa193e8ab5e05db0bcd83579ff13712810d8a97f5b4c903069b7b79ec7882823e28551eb68569430d94427a09d0e1fdbb06997",
      "line": 860,
      "relation": "decreases",
      "source": 58,
      "target": 130
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, AF267B treatment leads to an increase in alpha secretase, which is an enzyme that can prevent the production of AÎ² peptide",
      "key": "a6e2d14a898afc73dcdba61ab9002aaaf9e74a2e4c5d053437a8644d13acf8ba6ff34ad80ad70722b9aca017a5ded6b6ca18f32787ad5e341922a66fc21ee2ab",
      "line": 867,
      "relation": "increases",
      "source": 58,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, AF267B treatment leads to an increase in alpha secretase, which is an enzyme that can prevent the production of AÎ² peptide",
      "key": "5e1c86b121dc9766cfe2302fd36e19478553b4769b0474ebcd32a8810f75caddd6e1124bc0343bce67c9dd919930e83a8f6fb807234143c863785fc867aeffac",
      "line": 868,
      "relation": "decreases",
      "source": 40,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "key": "90bc0a3d9172135e1773c9bc1e31c096c673500d39cfb5623459ad9462e21e45725f45b861d41e543111d73dc4337bc8cc7b81c8d4e92eef903f5326828b8a47",
      "line": 875,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 60,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "key": "c0b8089791d9c41ff9a8ff5a252847c13e74441e9ca55995e0cef34a603ee520bab599a850a8285994ce259a8fad387af436bc82dd9f3b20119ea27f73d9d8bf",
      "line": 877,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 60,
      "target": 105
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "key": "5505f52f2aa972bc589024235e62d3192858217a43d82593f9fa2d48ca22f91639489c3ca76161c56dc6c5406a0b96d4feb958a89cf38dbcf262406534f06666",
      "line": 878,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 60,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, the use of M2 antagonists, such as SCH-57790 and SC-72788, can lead to blockage of M2-mediated inhibition of presynaptic release of ACh, which can activate M1 and nicotinic receptors, ameliorating cognitive impairment in AD",
      "key": "8097037a4ca3491d6ce4427f9cecdb91e1fe35c42c4cd0d6dc51555954f71a0646856c2f2b15ff464d192b6d1d8d459797979b5bead36ff0c40a8c11bb2f7c91",
      "line": 879,
      "relation": "increases",
      "source": 60,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "key": "8696d1becbc5307b910502e581501ad9de863cd158a37ebbe55236dd1132e1105feae76293f6af52d560da44952e06ea4a0aa3b0aaeadb604e1c4719b92f18e6",
      "line": 902,
      "relation": "increases",
      "source": 33,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "key": "650998ee6af66c5302005dee41b0644d62ac68d11525ec166ea0a3dc758561c0535379f60a5ebb8e6fac06dd0665dda6faa1ff91b97887ca3fe61200d23d84eb",
      "line": 903,
      "relation": "increases",
      "source": 33,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "key": "73db74feea35b78c05a386d865780207f2fb57f8d2f9be22206edf78230951232ca706b0d58d61dd638262207781048098bb866deb61b82914b380322f59de3d",
      "line": 904,
      "relation": "decreases",
      "source": 33,
      "target": 147
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "key": "f7335d7157418cb697eacfcc8e97930733f46b442c3a985242e9eb740ee8484e6fce7e1edd2a1ced314853c063bef115eee80e673959cf6c2b02139eda823ea4",
      "line": 905,
      "relation": "decreases",
      "source": 33,
      "target": 151
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations",
      "key": "4a3ef3af0a2b45308b2f281b46185f014398dcf9646bbfb69ce010e8b44ed9f974d3e3580a317d944c2327ec3c921dd7e2a21bdf592a3c68122072605367f3d8",
      "line": 906,
      "relation": "decreases",
      "source": 33,
      "target": 158
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "For example, it has been shown that the benzyl quinolone carboxylic acid (BQCA), which is an M1-selective allosteric agonist, is effective in increasing spontaneous excitatory postsynaptic currents in the medial prefrontal cortex (mPFC) pyramidal cells and improving memory in a transgenic mouse model of AD",
      "key": "1618c84c80af4df479bcb366fd291aedeff35229047f59a2561a50d86c4d76de4184e9efbd137d98abdcbef9efe81f19bdd0cd81b56f6137f949fc23115a17f6",
      "line": 917,
      "relation": "increases",
      "source": 59,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "For example, it has been shown that the benzyl quinolone carboxylic acid (BQCA), which is an M1-selective allosteric agonist, is effective in increasing spontaneous excitatory postsynaptic currents in the medial prefrontal cortex (mPFC) pyramidal cells and improving memory in a transgenic mouse model of AD",
      "key": "8ad30f6fdb5f9bb04e6c8124d5f3cf9d9729d18504a75d08a02a4484449d51d25784fe4a38281c1cfa3092f73b9776fee4af36ad4806af7ef72d55f348a24626",
      "line": 918,
      "relation": "increases",
      "source": 59,
      "target": 77
    },
    {
      "key": "c673d43cb9c0a13c104bd8b10da30edf48ad994aee93e9f4e229224e903f23ab144345247dd1989280be6cacf5667530fa1d419f875574abb870e45c60707a27",
      "relation": "hasComponent",
      "source": 87,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In fact, it has been shown that APP interacts with CHT1 proteins increasing their endocytosis from the cell surface [258] and that mice that display disruption of CHT1 gene expression exhibit symptoms related to ACh deficit",
      "key": "7cc358bdca5253c04c3bc5994b5e2d65bb8ccbf7b78bd8308310332e0c1c7c065fa1eecbcf7dcb64120bd28caba5c249f554dd52ab5df90ec88f95ddb8b3e42e",
      "line": 926,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "cell surface",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "intracellular",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 87,
      "target": 102
    },
    {
      "key": "d470464ad7ba995b8980ad390d32f3341c1933c0d30fe5b8e758473813fac90f712f0bd04f039444a831ce7c47b8ee87b42b2012f641d1450e1bb906059d67e9",
      "relation": "hasComponent",
      "source": 87,
      "target": 133
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "In fact, memantine is able to reduce the excitotoxicity in AD",
      "key": "184c398a0962bf30dec8076f6d89c1c3fb5e7d41d747dcf99f2883049437b93735f2f28f0557ac9657892fed0394bea802eadfd89660e73c63c92a92f5f427fd",
      "line": 931,
      "relation": "decreases",
      "source": 24,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Furthermore, it has also been proposed that the nerve growth factor (NGF) has the potential to preserve cholinergic neurons",
      "key": "0d3caf9ebe51d6cec42c63590be49586aff3ab72be0cf2409e6019717794cfdb5bac76a0b6423d2a17da177e53d4437b11f57fb4e00187bd7fd8db6d414fdca9",
      "line": 939,
      "relation": "increases",
      "source": 49,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, previous studies have shown that treatment with NGF can counteract cholinergic atrophy and memory deficits in aged rats",
      "key": "ec503016f6ddf0475da920bad2ef630cea747e9ace61e66d9a98fc6b49ba980d38a07a87495da809c3b95c8398a739945b42cba3864b5b370db826be9e1d11db",
      "line": 946,
      "relation": "increases",
      "source": 49,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferreira-Vieira TH",
          "Guimaraes IM",
          "Ribeiro FM",
          "Silva FR"
        ],
        "date": "2016-01-01",
        "first": "Ferreira-Vieira TH",
        "last": "Ribeiro FM",
        "name": "Current neuropharmacology",
        "pages": "101-15",
        "reference": "26813123",
        "title": "Alzheimer's disease: Targeting the Cholinergic System.",
        "type": "PubMed",
        "volume": "14"
      },
      "evidence": "Moreover, previous studies have shown that treatment with NGF can counteract cholinergic atrophy and memory deficits in aged rats",
      "key": "a686dd1934333d02663406f34d6914d6137da4689d22c81d62053da7fbb1febc3c0079e8aa154e53f4434e52937a9cc034200a105f1c900351ca5969d7216c7d",
      "line": 947,
      "relation": "increases",
      "source": 49,
      "target": 77
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"1,1-dimethyl-4-phenylpiperazinium iodide\")",
      "function": "Abundance",
      "id": "f6a683e1c97873337d3e8873ac2e002d60e709bec9d176f2b04e7e0ef15abd652928fdda1bb91a8103329c55b0f03b623db2b3ef3ee31a9f602c638fae446643",
      "name": "1,1-dimethyl-4-phenylpiperazinium iodide",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"2-(4-phenyl-1-piperidinyl)-1-cyclohexanol\")",
      "function": "Abundance",
      "id": "784f30a25a8035404bdc40e1901d2ead95aa7cb4a896a4877001a8133c486ffc209977d72c84767e8d00ba12712ffdbdaa5ff88cba49e08ec294aaf6f0a0adcc",
      "name": "2-(4-phenyl-1-piperidinyl)-1-cyclohexanol",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"3',5'-cyclic AMP\")",
      "function": "Abundance",
      "id": "e634e1d295920557f5cf0c1b3fd2bf18d082b00fb983d6632b989552d1ba51e14a88952b3abfc55d7ab65f035c7e90d951497cfa11719f0492edab0ddb91813a",
      "name": "3',5'-cyclic AMP",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"EC 3.1.1.7 (acetylcholinesterase) inhibitor\")",
      "function": "Abundance",
      "id": "f5115583612f3f2c40ebc54f2c528dbe7732517483538bd78de15d36df42904885a4fb82e5b4feac53e21bbdcf5c7e8e78c1985c4ff40c3fe99509119cf8984b",
      "name": "EC 3.1.1.7 (acetylcholinesterase) inhibitor",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"acetyl-CoA\")",
      "function": "Abundance",
      "id": "a5fa305d2e2001d715f893ae6c2d622f7e9190eff20a4c42d6ac7af0177896d9464cdd5304827d22ac2fce8b653837ad54d0a95422b99f8fbf8e348571b0e739",
      "name": "acetyl-CoA",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 42\")",
      "function": "Abundance",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13",
      "name": "amyloid-beta polypeptide 42",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "function": "Abundance",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2",
      "name": "amyloid-beta",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"calcium(2+)\")",
      "function": "Abundance",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9",
      "name": "calcium(2+)",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"gamma-aminobutyric acid\")",
      "function": "Abundance",
      "id": "9583f9418a889245078b43a5744b3aee37f76bff3bff369f21f4091c2ad475d69415b09ff3b3b7e7aa6014f4e5dab6706477099218ce8a665f6751daba94e6b3",
      "name": "gamma-aminobutyric acid",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"glutamate(2-)\")",
      "function": "Abundance",
      "id": "9749d43ec7dd166b90348b70de96bca3f824fa7c4624aa5f0d82f2dbd2e1d559cccd5b7e74c86268f2e152cea542c1a7c99fc9b98d5d12853d44f9a56b615e4a",
      "name": "glutamate(2-)",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"myo-inositol\")",
      "function": "Abundance",
      "id": "8e30147d621df97bd65d9a05469574cdb77f6e0ffcd739a2cd3f2df34226380c7343ade60b8b2c463d586373a4d2df216e2c743a9c709a568ab5fdd95472dc76",
      "name": "myo-inositol",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"organophosphorus compound\")",
      "function": "Abundance",
      "id": "fb2bd16451ccd43d230f62f14b1ce9a26599b77e495c4d140a6d02e7d1723c81ea1f3083f3464a10b696289f7011eb26017f4186abd7821415b2e880b3a6334e",
      "name": "organophosphorus compound",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:Mecamylamine)",
      "function": "Abundance",
      "id": "f81a5cca79277a3483157d6067c10b7916d6c4e183c85db0a42f5f427ebe2280a46a47f3899a13dfa89025b0f2b6dd3a0b02b3240d27c1c06be3d4a662516041",
      "name": "Mecamylamine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:Muscarine)",
      "function": "Abundance",
      "id": "cd8810a772826fa19ba15a5cd85ae7c504be5704a846c278af3686e509f6111061dd3723150cc75f9bec9a118f6dd0ca90a0c9cec1f6a7f2b90fc754c281ca05",
      "name": "Muscarine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:acetate)",
      "function": "Abundance",
      "id": "d5ded90176d5afa9f66d7ba0409d88511fae64124dd5180c6295d21039a13c0acfa4ca0169c04feb91a4195659923665085980b3745f5473e1b4e88b5c54686f",
      "name": "acetate",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:acetylcholine)",
      "function": "Abundance",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62",
      "name": "acetylcholine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:antidote)",
      "function": "Abundance",
      "id": "7ae930003e91de197f2d5b15805449a8ee2b3d9d81c78bdbba6d32598295fbca92a3c428b9c792e4c38eebf565205d4418c5a6e2abfc95c121e34468a0843666",
      "name": "antidote",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:atropine)",
      "function": "Abundance",
      "id": "e6e78f2f05d79f22e492e95616d895732bdd6244a2994a505f12cc72171d74cbe0826256e86bbfa87c18e6f15bd53e5765abccaf3c49acc948f5bdac58167bdf",
      "name": "atropine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:choline)",
      "function": "Abundance",
      "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee",
      "name": "choline",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:cystine)",
      "function": "Abundance",
      "id": "9e771036593d5eddff7c598b683d7862a0506aa51edf075654e51497b95a147f688f7576b8285f242ada6d10e1cc63d6c81f645233005ba2fec74d889e90dd07",
      "name": "cystine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:donepezil)",
      "function": "Abundance",
      "id": "e1d832febdffe3cc8c4fa21718e0b21719272a1a10c2945cdd3b36cc6ff66c3ec70289ed1ddc3a7a6b79ca44a4bc0fac6ecb12683fc043cdac26b952f7cf5223",
      "name": "donepezil",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:dopamine)",
      "function": "Abundance",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e",
      "name": "dopamine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:doxylamine)",
      "function": "Abundance",
      "id": "5590d4b6c165cc71a80a2df8f9ed51c0d035786a9c8f803ddaab7e826c7afc8fd5838c2128eea66f6235b53aca45333af40b3914d7b7abf739c1fdaed9fe8ffc",
      "name": "doxylamine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:galanthamine)",
      "function": "Abundance",
      "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57",
      "name": "galanthamine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:memantine)",
      "function": "Abundance",
      "id": "a6417701f850dae3b77bc52ab06561523bf34757aa461d008c48b9b489cf2293a3fb2bd592ae99ac7d23dd6143614f12df64ef718109abeaf9651954c612bfe7",
      "name": "memantine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:neurotransmitter)",
      "function": "Abundance",
      "id": "bece6d10e96b69785dbd4c8bab8cbdcd754ff9a5139cabd93dab71c006f16c4b150a518aa934dc852c07fe26a629610104fdc8695476b406a886a07b935c6ccd",
      "name": "neurotransmitter",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:nicotine)",
      "function": "Abundance",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8",
      "name": "nicotine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:noradrenaline)",
      "function": "Abundance",
      "id": "4553f1e4c5c615e68013cac87f15df1fff14c0afbce0727cddfcb8329488f1dbcb9f1fd9b88f78d222bb7b5cc67d2c05a5e1fad860c45047b0fac2778cb1ffac",
      "name": "noradrenaline",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:proton)",
      "function": "Abundance",
      "id": "656f481121cc6acad3e40670e0ce89ddb10a6953ac369b676e1dd716269b4ea0cfb7ea117ab37d4a5e8d4ba20d5f59f165dd50390a12b0d8f40f289184a6d8cb",
      "name": "proton",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:rivastigmine)",
      "function": "Abundance",
      "id": "317d5b18448e148088204c7a7dce78316c0ea8b56c70a7adaffe344826b17688e05873b2746050d29c18ae658658e81a2d775ba56b6f5abf8821f4eaca725064",
      "name": "rivastigmine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:serotonin)",
      "function": "Abundance",
      "id": "8d7ceea95cec905de8941facf48d632e3c509b6ce451f835af1fab5789daacc5bbf8d1bdb7cfd90863a70871a9a9a07b093896248712aa6567895ae8cf3b3502",
      "name": "serotonin",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:succinylcholine)",
      "function": "Abundance",
      "id": "9be71e5c65ebe878c2ffbe016440990d03335150131fd5176a24e764968a672981f703777d758d3c2f9deb29328aa0a570286a74dd1e55f8c844e0055e0de491",
      "name": "succinylcholine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:tubocurarine)",
      "function": "Abundance",
      "id": "01c474637c37396cf09ff718da02e0251a043b483e26f84f6586065d4c0b50bf21418f8c5b1d4764993a68f120a98d1df2d2bfad03e6e974b7e85ab657214d82",
      "name": "tubocurarine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:xanomeline)",
      "function": "Abundance",
      "id": "2fc0c8095fa7470cf35b39ec64fdafb13d4aacaa5cf5fccb346bad55c7db083afc2172727fe8e5e1b11eedbf583482aa264cc408edc9e39f1d6e3a6ce1771a02",
      "name": "xanomeline",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(GO:\"cholinergic synapse\")",
      "function": "Abundance",
      "id": "4c170e68c3f3b683b948384db96f32d3b0cc1acefca0bc761ee56ad72f1e866862673a07a4755e10af696ed903fb018f1c53dc9cf0a73ede83b8faaa63439b04",
      "name": "cholinergic synapse",
      "namespace": "GO"
    },
    {
      "bel": "a(GO:\"plasma membrane\")",
      "function": "Abundance",
      "id": "c91ba9314a78745ee8bdf730be5f8fba1efe5b19352680209444bba471ba7c43aa52e010a74d94e49d1ab3d264e955ae635de541091819e5314c6ba3f8e43d45",
      "name": "plasma membrane",
      "namespace": "GO"
    },
    {
      "bel": "a(GO:synapse)",
      "function": "Abundance",
      "id": "cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74",
      "name": "synapse",
      "namespace": "GO"
    },
    {
      "bel": "a(HBP:\"amyloid-beta fibrils\")",
      "function": "Abundance",
      "id": "67b4c76bd9f06b116883a58eaa40e8453f2fda318ae9313477ebc24c6d04613ea373fdf611fd8a740de5a090826662d88c39f2ab166bca226cc8237cb0c71a1a",
      "name": "amyloid-beta fibrils",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"amyloid-beta oligomers\")",
      "function": "Abundance",
      "id": "a0fc661406161db12bdd89333a13d0ee89b3aa089d5eb16676962cae3efd25d4d3dd6e593dbcaebf5fc0c26f9c8c070a98f2ff0fb94a0d52412c0fa0bf6c5b3b",
      "name": "amyloid-beta oligomers",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:Excitotoxicity)",
      "function": "Abundance",
      "id": "80f0fe9786f726038f985feb4dc24c6add06927628a431fd67220bcc4eee6f64d44b062beb6925b2e5d96998987c03cbc272ea5e23197ce62e58cf17fa7517b7",
      "name": "Excitotoxicity",
      "namespace": "HBP"
    },
    {
      "bel": "a(MESH:\"Amyloid Precursor Protein Secretases\")",
      "function": "Abundance",
      "id": "e5dba1c4bad02dc976d1f20721664d15bb41a252b81651e0af45702b2bae4eee08a93f702d9aca34394ee6533849b56a6cb30da31d0a3a042b3725a02c4cfb9c",
      "name": "Amyloid Precursor Protein Secretases",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Amyloid beta-Peptides\")",
      "function": "Abundance",
      "id": "3561a0e32ad8cad6085b532574f73a3cce1d90648f557d9658ffd734fa10825a5ee8e45f868eb74a3ea6acb478fc4145667df43b0f1205da1a00ea642995747a",
      "name": "Amyloid beta-Peptides",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Basal Nucleus of Meynert\")",
      "function": "Abundance",
      "id": "55791b8db49179c5e2f02c74d5056d8d60e4fa71f21e025b774bf9dadb8243c6e0dfbc7537f386152a81f84dd6ed7b3dc4dcd803d10368f0d57611d244dbf792",
      "name": "Basal Nucleus of Meynert",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Calcium Channels\")",
      "function": "Abundance",
      "id": "717197b61b759ef2be3144c29f03429113fd927dd475a37f66ab129f4ec169f72cd116e4d75aed0c7c7dfb71a6702a0e1bfb1155246f50ffff060565ace36ff0",
      "name": "Calcium Channels",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Chloride Channels\")",
      "function": "Abundance",
      "id": "99ce372338919d9555406ae988509f576406c8ff148ca506ed80361d69ab9e73f6de1062d2cacd115298dfc074587a9414591cb275ecec679d8069d49ad6c639",
      "name": "Chloride Channels",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Cholinergic Neurons\")",
      "function": "Abundance",
      "id": "475e93ca136a9e7794a0aa5f656e5e5514ae3be3984ee430b1c69e597fa87e955ab73e3aa428c790e154477727ce382f73ecadc9ea6ee58ce4366c0b4ed73765",
      "name": "Cholinergic Neurons",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Cholinesterase Inhibitors\")",
      "function": "Abundance",
      "id": "b252d42b2ecbfb68db87f06416ccc08afa0d99fb328e5a261206ea6cfae0f6159ac06185addd43240e53ca82a6e028163b36fa5169bd7f418dcfd205f7ca7269",
      "name": "Cholinesterase Inhibitors",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Hypothalamo-Hypophyseal System\")",
      "function": "Abundance",
      "id": "01d1ec2c85eea238b63790147fad4d79c05a4a74490792466801a098c1a56288f50f3bb027491d0b2fb54977d83355bf5f5ed4ff57a0379dc6a597da0a753507",
      "name": "Hypothalamo-Hypophyseal System",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Ion Channels\")",
      "function": "Abundance",
      "id": "5d18aa69556b0ee1bc6e62c486d2fdb103ab46f8f3efaa335925c2bc8087a311b1ba2062efccc91585dad46ec1ea90f10d46eddcc365e130013be3eb08beff68",
      "name": "Ion Channels",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Nerve Growth Factor\")",
      "function": "Abundance",
      "id": "e39eee0b24c33d4c98fd121d6d3c6686cd8d8c439f9a6df9b924ff73dac127a4aa68ddb575a9af05c73c61fd741ed0cec55012cc562b7856ea595a47f64e57df",
      "name": "Nerve Growth Factor",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Potassium Channels\")",
      "function": "Abundance",
      "id": "46b1db29da1ded5d0ce08e722461346e513844902c7900bea4921bb49ec48c73b6f0872a558ddee5594d55d007f25271413ad8761215ab8880ce65d0d1faf4a3",
      "name": "Potassium Channels",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Protein-Tyrosine Kinases\")",
      "function": "Abundance",
      "id": "6f56cef42f9cab1b2e659ca27e12c0cf76ec61abb71f938b6663468e344f8192b34800498b115fa669f8054311f47f8cf23b526297843866bda8d8f66ac39e0e",
      "name": "Protein-Tyrosine Kinases",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Quinuclidinyl Benzilate\")",
      "function": "Abundance",
      "id": "62c4733f9943b6aaf4024b6dcd7001d8dc832bc1cfedca9a476ef83a788730fad3df469de15f562c1ab09132e4a5664dd27a22feae182fedc04920b92be3ab6d",
      "name": "Quinuclidinyl Benzilate",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Receptors, Cholinergic\")",
      "function": "Abundance",
      "id": "d3bf8fdebccce142752b9fc8505dbbf0b20681a2282315d7e14f15ef75281690d8bc75e6b66c170ad6f85c246d4cedb6cdc3b4ba719bd4d622c3a1e2a60d96c8",
      "name": "Receptors, Cholinergic",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Receptors, G-Protein-Coupled\")",
      "function": "Abundance",
      "id": "7fc54d93408c787fd4827f788b4ae387d42fd1211c898ba47b57d8aa21006153f1bf55db595962c866b6cde8754ca2d14f2d0a186101f2b989cef1ab3444ac76",
      "name": "Receptors, G-Protein-Coupled",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Receptors, N-Methyl-D-Aspartate\")",
      "function": "Abundance",
      "id": "bc0c849274509856f0839b39c84ee4c4d06be886e9c4a160c019e566da4f7b7da0f773b5326d9d72ab53f350fa5ff3371b3cf66ae89e844579e4eb6102565963",
      "name": "Receptors, N-Methyl-D-Aspartate",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Receptors, Nicotinic\")",
      "function": "Abundance",
      "id": "ab9ab8a42f27ea8b317e817b34a7ed7609808e3ccad71f0ce8685fa7b9e53fd847534ce7483452cc11f2166657f178e8e6804466c34019ef9674372b725b155d",
      "name": "Receptors, Nicotinic",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Neurons)",
      "function": "Abundance",
      "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643",
      "name": "Neurons",
      "namespace": "MESH"
    },
    {
      "bel": "a(PUBCHEM:10013505)",
      "function": "Abundance",
      "id": "ed6952bde5750309170d0b7df493e5f17979a541ce04d231a70ea6221f14953753b68a2d0524f1893d2b32af38c7d75414157a8fd84eab0ca95126a6b59712f4",
      "name": "10013505",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "a(PUBCHEM:1476756)",
      "function": "Abundance",
      "id": "fac3414862f2ee2342e4301cd75c1f6074a14b16163361e822649de6891909b8c75926396b631290723b5e5c1c6d0cfdcf0333e084c81d1620b42dc705da8123",
      "name": "1476756",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "a(PUBCHEM:9867750)",
      "function": "Abundance",
      "id": "59ed44f2cee63eb7e58fbc123de1917d6b565856494a777c7cd9bb40f5db3f4ecb6e331c5ceae9e45a38b0150eedc54ba1bded4443bd7fc61b898f75ccc9b8db",
      "name": "9867750",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "bp(GO:\"action potential initiation\")",
      "function": "BiologicalProcess",
      "id": "6f51801f7e712519f75d8699aeffb6f9ac5ae8a8feba5cf3ba5a31d577139528e758d50531ba27e799f3c68a86e5dc61a998a23ac14848a007b70122a89ddbeb",
      "name": "action potential initiation",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"calcium ion import\")",
      "function": "BiologicalProcess",
      "id": "59aba019a24c9b594bdb11c260e05c8c44271642e0bba57cee0d8344900dd37926650926918af680b9817401f222a60b89e3ee614ca2c800bb8ca4decf5e6d1e",
      "name": "calcium ion import",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"circadian sleep/wake cycle\")",
      "function": "BiologicalProcess",
      "id": "6b7726173384f8eb927b7a773d744b2cdfb332c69f6d4ada3109cb6f66b163ed2ee53fe97142ff0cebaf797aa81de111046b936c028e1c0191455e9d03ab9781",
      "name": "circadian sleep/wake cycle",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"circadian sleep/wake cycle, REM sleep\")",
      "function": "BiologicalProcess",
      "id": "994160c96a6d0ac2b178e9fbda9b705b8870dc8ac9b6068100d1cc74a25655738da752866b230c4c34f9e4ff3750c8730949f8c41326959a4bcead720bdfd355",
      "name": "circadian sleep/wake cycle, REM sleep",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"excitatory postsynaptic potential\")",
      "function": "BiologicalProcess",
      "id": "7530abec480fef9088630c7c75659c3319b25c0203b3f1e783da5dad1de92f5a07a2124c9fb223f91468243fc3f14894ac43b624ced9fa8405b9151b240b85e1",
      "name": "excitatory postsynaptic potential",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"membrane depolarization\")",
      "function": "BiologicalProcess",
      "id": "e39ac862551cfbabee553faf7cdf77b10d143e9ff3adb94c30b29266575efc988ceb9f023c9c3092ce7eb4f4f002154cd839d4a358db03ef35e2da80ced957f5",
      "name": "membrane depolarization",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"regulation of circadian sleep/wake cycle, sleep\")",
      "function": "BiologicalProcess",
      "id": "a29191da4da82e1a0046154bbcc26bcf4a64a7148e0371eaaf3fa4a632075f318889d4679c4155e4305346972b2fa5ae92be0244fdf7a49fa984f2796328aecc",
      "name": "regulation of circadian sleep/wake cycle, sleep",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"regulation of circadian sleep/wake cycle, wakefulness\")",
      "function": "BiologicalProcess",
      "id": "69ed7881730254280889a8f4e85ee366a5e1b581f120dcfc29a6ab45b268c0e9bc0877479d22c3a986cda5a050940e28cb156c8f63aff59b62eb76dcbdb3708e",
      "name": "regulation of circadian sleep/wake cycle, wakefulness",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"response to auditory stimulus\")",
      "function": "BiologicalProcess",
      "id": "ba7c7b5dc61985a667995d1f4ea6da9d8c00fec7be25288bf51c2f4e9824cdf9a34049c8f1841fa021d851c8a245acbea0013d97a97897bc49ce6b8f1299c51e",
      "name": "response to auditory stimulus",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"response to stress\")",
      "function": "BiologicalProcess",
      "id": "6fa75459766cad2fc6b7a639d1866b76e32fe67fc60da0c4813032337226b441dfdb2ef161f19ab85095fc3aa6a4538d309d2c857d6195f021bbdf91fd6ee683",
      "name": "response to stress",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"sensory processing\")",
      "function": "BiologicalProcess",
      "id": "338b23e2a14b6d541045638df25f7aefab6baa1d3f68fd54f38be131d2de6d14b634ded4037568e49da2ef9ddc8e37d835264ba41ed87cee3665b81d932fa042",
      "name": "sensory processing",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"synaptic transmission, cholinergic\")",
      "function": "BiologicalProcess",
      "id": "4238cec14ccdcd7b90d308eb0687f5775f5b1ed79362c1d84004721894a52040968a92b357a6bf971a144e903a9b441d8be9ba5ee78e5e039c5f83c167933575",
      "name": "synaptic transmission, cholinergic",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"synaptic transmission, dopaminergic\")",
      "function": "BiologicalProcess",
      "id": "30e4d389cce3682af2cd604d08a33dd5d8aa502d5fda93a9cf7ad8ee4d033ee8e9e72d4fb7082b622fae5d7648457514171c04400da110e5eeee4f6d38b23fd8",
      "name": "synaptic transmission, dopaminergic",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"synaptic transmission, glutamatergic\")",
      "function": "BiologicalProcess",
      "id": "68a9f5219c953044883133bf5f935c2f9a074b8e719aa33dc0766bba8dd98b92cefd134205b93bd6f586b594e1438d307a554c9771bccd03dc6acf03e09bb82c",
      "name": "synaptic transmission, glutamatergic",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:cognition)",
      "function": "BiologicalProcess",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127",
      "name": "cognition",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:learning)",
      "function": "BiologicalProcess",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633",
      "name": "learning",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:memory)",
      "function": "BiologicalProcess",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd",
      "name": "memory",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:neurogenesis)",
      "function": "BiologicalProcess",
      "id": "ccb2f3e257c49dabd7cf3eeba8cba8fd30968c1bdc7f9e804ced60fd0924e48804ff5f7011ae262bf7de0c708d68125f16ec1341eb14218ff0a4596f3adeac55",
      "name": "neurogenesis",
      "namespace": "GO"
    },
    {
      "bel": "bp(HBP:Neurodegeneration)",
      "function": "BiologicalProcess",
      "id": "8f63d9ba3869712b675d29e11f0c0fb09685ddaec0a3a1584becd70b306380d15de58814844a018655820ca2a6e6eca66b0ec6a21ec2e428e8a52dc13eeff56e",
      "name": "Neurodegeneration",
      "namespace": "HBP"
    },
    {
      "bel": "bp(MESH:\"Synaptic Transmission\")",
      "function": "BiologicalProcess",
      "id": "029ab128c5f88cb19d194601faa91ab7741b2fd933156dd2d47e360ce2f97abea415665dbac7bce169ccbcfd285c1628aacfeb15bb6ed2025876778dcc6b8360",
      "name": "Synaptic Transmission",
      "namespace": "MESH"
    },
    {
      "bel": "complex(a(CHEBI:\"1,1-dimethyl-4-phenylpiperazinium iodide\"), p(FPLX:CHRN))",
      "function": "Complex",
      "id": "e51486545f3de9ac22ce959d6e705012e8d7800c37ce71e105cde02b38ed2e4a350e78a99c252643ea58e1e7d8e93a14336386f8486b24f98d05b551585a9c47",
      "members": [
        {
          "bel": "a(CHEBI:\"1,1-dimethyl-4-phenylpiperazinium iodide\")",
          "function": "Abundance",
          "id": "f6a683e1c97873337d3e8873ac2e002d60e709bec9d176f2b04e7e0ef15abd652928fdda1bb91a8103329c55b0f03b623db2b3ef3ee31a9f602c638fae446643",
          "name": "1,1-dimethyl-4-phenylpiperazinium iodide",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(FPLX:CHRN)",
          "function": "Protein",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5",
          "name": "CHRN",
          "namespace": "FPLX"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:Muscarine), p(FPLX:CHRM))",
      "function": "Complex",
      "id": "06c28f83e19d053cf49d5d2edfe04b9a39540b0dc238dbdf569478e51e780a2e160ccdaf032fde1730b0a2dc43376f2a693a6d8683f4a22924066eebc8c6223e",
      "members": [
        {
          "bel": "a(CHEBI:Muscarine)",
          "function": "Abundance",
          "id": "cd8810a772826fa19ba15a5cd85ae7c504be5704a846c278af3686e509f6111061dd3723150cc75f9bec9a118f6dd0ca90a0c9cec1f6a7f2b90fc754c281ca05",
          "name": "Muscarine",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(FPLX:CHRM)",
          "function": "Protein",
          "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba",
          "name": "CHRM",
          "namespace": "FPLX"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:cystine), p(FPLX:CHRN))",
      "function": "Complex",
      "id": "fc46bbc014ee05128c1feb8156c73043fb2bf6e24547533665c355d2c5d2a6885389f3907b3afc1d140dd51c7ac201e237673612bacbc2a72fb85fe413591c01",
      "members": [
        {
          "bel": "a(CHEBI:cystine)",
          "function": "Abundance",
          "id": "9e771036593d5eddff7c598b683d7862a0506aa51edf075654e51497b95a147f688f7576b8285f242ada6d10e1cc63d6c81f645233005ba2fec74d889e90dd07",
          "name": "cystine",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(FPLX:CHRN)",
          "function": "Protein",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5",
          "name": "CHRN",
          "namespace": "FPLX"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:nicotine), p(FPLX:CHRN))",
      "function": "Complex",
      "id": "755001b9784553af9df52f25761d4d597267afe4d5d8fb257e62b5589d2625063ca94672b56cf87dd40ac4cd9104d8fb9c1a9fb3afd996c5e197e651b892512f",
      "members": [
        {
          "bel": "a(CHEBI:nicotine)",
          "function": "Abundance",
          "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8",
          "name": "nicotine",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(FPLX:CHRN)",
          "function": "Protein",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5",
          "name": "CHRN",
          "namespace": "FPLX"
        }
      ]
    },
    {
      "bel": "complex(a(GO:\"plasma membrane\"), p(HGNC:SLC5A7))",
      "function": "Complex",
      "id": "706fba2bf76d9b751c81f031b8eb133cbbd1a5cc8f1f8e12ade6364c11c9c76fb9732c0a4da8de6a6c8eeaf1f85e247cc914f491d2cabf1242ad7a040982938c",
      "members": [
        {
          "bel": "a(GO:\"plasma membrane\")",
          "function": "Abundance",
          "id": "c91ba9314a78745ee8bdf730be5f8fba1efe5b19352680209444bba471ba7c43aa52e010a74d94e49d1ab3d264e955ae635de541091819e5314c6ba3f8e43d45",
          "name": "plasma membrane",
          "namespace": "GO"
        },
        {
          "bel": "p(HGNC:SLC5A7)",
          "function": "Protein",
          "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50",
          "name": "SLC5A7",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Amyloid beta-Peptides\"), p(HGNC:ACHE))",
      "function": "Complex",
      "id": "6535cee244f55a596d042ccb1e31d2a16efe4cc4a26d2601f69a67825f04e443fad11c76e9b32d401d3093a0f97ca8be8e3e95d75418fd54e276d98f239c1ef4",
      "members": [
        {
          "bel": "a(MESH:\"Amyloid beta-Peptides\")",
          "function": "Abundance",
          "id": "3561a0e32ad8cad6085b532574f73a3cce1d90648f557d9658ffd734fa10825a5ee8e45f868eb74a3ea6acb478fc4145667df43b0f1205da1a00ea642995747a",
          "name": "Amyloid beta-Peptides",
          "namespace": "MESH"
        },
        {
          "bel": "p(HGNC:ACHE)",
          "function": "Protein",
          "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f",
          "name": "ACHE",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:APP), p(HGNC:SLC5A7))",
      "function": "Complex",
      "id": "56d9fabb464cfd62e36d26ba24b44c91d2708879a5f6a63f1162f6df19f2096251b34e48d80d3fee7153ed65433acece67da32f1888ec614f9f9289caedba12e",
      "members": [
        {
          "bel": "p(HGNC:APP)",
          "function": "Protein",
          "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc",
          "name": "APP",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:SLC5A7)",
          "function": "Protein",
          "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50",
          "name": "SLC5A7",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM1), p(INTERPRO:\"G-protein alpha subunit, group Q\"))",
      "function": "Complex",
      "id": "e243c308f64a88d011e51b5fddb3f44996e850eae75e2d32f95da59937533406389e0ba4a846a4a61c720b09cd864abddfd52ad77feb9879dba2621f337b3a93",
      "members": [
        {
          "bel": "p(HGNC:CHRM1)",
          "function": "Protein",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
          "name": "CHRM1",
          "namespace": "HGNC"
        },
        {
          "bel": "p(INTERPRO:\"G-protein alpha subunit, group Q\")",
          "function": "Protein",
          "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77",
          "name": "G-protein alpha subunit, group Q",
          "namespace": "INTERPRO"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM2), p(INTERPRO:\"G-protein alpha subunit, group I\"))",
      "function": "Complex",
      "id": "ad9ae3574b94e47fd3f6567a24140fce6be957c6ce11810d604498e44de0c78f86e529407cb37743f9be8b3b681de9e23069ed6955627d501ae650646e14ef0e",
      "members": [
        {
          "bel": "p(HGNC:CHRM2)",
          "function": "Protein",
          "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5",
          "name": "CHRM2",
          "namespace": "HGNC"
        },
        {
          "bel": "p(INTERPRO:\"G-protein alpha subunit, group I\")",
          "function": "Protein",
          "id": "565d5a0ce05389cc28d32063238cc00ce7632812ed30abd3835743988317db88f8b40881c918c9a9216139a14c4a046cb4ee8d4abdd55fa5cc9ed22b77a1075a",
          "name": "G-protein alpha subunit, group I",
          "namespace": "INTERPRO"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM3), p(INTERPRO:\"G-protein alpha subunit, group Q\"))",
      "function": "Complex",
      "id": "0a78f83d6243e9b9a4be2366872e83b3dc0a1f5e458204da1f65a7f75a2cb3aad5260314ffc4657fd15bf5f6c8d28d668118858ecdac370ee7e06cd9f0dd91b2",
      "members": [
        {
          "bel": "p(HGNC:CHRM3)",
          "function": "Protein",
          "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff",
          "name": "CHRM3",
          "namespace": "HGNC"
        },
        {
          "bel": "p(INTERPRO:\"G-protein alpha subunit, group Q\")",
          "function": "Protein",
          "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77",
          "name": "G-protein alpha subunit, group Q",
          "namespace": "INTERPRO"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM4), p(INTERPRO:\"G-protein alpha subunit, group I\"))",
      "function": "Complex",
      "id": "ce0ffc3af1310b2587b31cffe6ecfcad04993a678c020277d5c37fa52b4c7b1c8f5890665f317b2dc5b5f87ffb23bdfdb778500f8bb9d5d80f8c922f84ee1861",
      "members": [
        {
          "bel": "p(HGNC:CHRM4)",
          "function": "Protein",
          "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969",
          "name": "CHRM4",
          "namespace": "HGNC"
        },
        {
          "bel": "p(INTERPRO:\"G-protein alpha subunit, group I\")",
          "function": "Protein",
          "id": "565d5a0ce05389cc28d32063238cc00ce7632812ed30abd3835743988317db88f8b40881c918c9a9216139a14c4a046cb4ee8d4abdd55fa5cc9ed22b77a1075a",
          "name": "G-protein alpha subunit, group I",
          "namespace": "INTERPRO"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM5), p(INTERPRO:\"G-protein alpha subunit, group Q\"))",
      "function": "Complex",
      "id": "ac5162ffe856bd72e58478396104e20bf9009049c3acccc74a21e35c8d66523c765ff69052127cb0de833499a7a046c462261ec019ff6c7b3769d334aa36567f",
      "members": [
        {
          "bel": "p(HGNC:CHRM5)",
          "function": "Protein",
          "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b",
          "name": "CHRM5",
          "namespace": "HGNC"
        },
        {
          "bel": "p(INTERPRO:\"G-protein alpha subunit, group Q\")",
          "function": "Protein",
          "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77",
          "name": "G-protein alpha subunit, group Q",
          "namespace": "INTERPRO"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRNA1), p(HGNC:CHRNA1), p(HGNC:CHRNB1), p(HGNC:CHRND), p(HGNC:CHRNG))",
      "function": "Complex",
      "id": "a4801106db4a49d613771d32ab40c9fe7e47086d34e4c4f6eca41cadd9d4656235993bd7bc595242694e66eb64e2d133c7c231cfd711c04c0c50dc847e2b61b7",
      "members": [
        {
          "bel": "p(HGNC:CHRNA1)",
          "function": "Protein",
          "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f",
          "name": "CHRNA1",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:CHRNA1)",
          "function": "Protein",
          "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f",
          "name": "CHRNA1",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:CHRNB1)",
          "function": "Protein",
          "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770",
          "name": "CHRNB1",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:CHRND)",
          "function": "Protein",
          "id": "0fc12a3743f6213b0a8c9854f102f96f98b6d4ca5f6b93243215c6be9ef59d1071e4a981dfef35497424c052ed7d381aad79e113dad69e8c322a85d581ef69e9",
          "name": "CHRND",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:CHRNG)",
          "function": "Protein",
          "id": "fdc2324c7ab13b542120da2e930dae1aa2c84562e3bc9a659ddf97ae7412bf4cd7e8ad8fa72eca411b79eb3b1dc8c21dbdeb575bf3d6015c33aae8e21ca0cdf8",
          "name": "CHRNG",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "p(FPLX:ADCY)",
      "function": "Protein",
      "id": "b36d4dc9944654bf1f5e6f33f03dbc76cc83f2880a08df6035e6112f55972272204b89f6c77f04b26ab30a6a47686da040163db4333a0d290c87dea9732b3087",
      "name": "ADCY",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:CHRM)",
      "function": "Protein",
      "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba",
      "name": "CHRM",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:CHRN)",
      "function": "Protein",
      "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5",
      "name": "CHRN",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:CHRN, pmod(Ph))",
      "function": "Protein",
      "id": "bf5da142a83cd1e07c52dee8368d5e6ad3811ae933a6716f57286b022234739d57d038c442ebee5af3d25ed396404c3e0a4d49cfd481a330827a381b92d012de",
      "name": "CHRN",
      "namespace": "FPLX",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(FPLX:PKA)",
      "function": "Protein",
      "id": "a312e28f30d661eb58c0cc3c07cda6812a6290acaa1b8c513be7a895fe1b15f1feb278ee6095359cd3e44eb43cf1864de0fd70d89d3cbcc5b18361fd31276f17",
      "name": "PKA",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:PKC)",
      "function": "Protein",
      "id": "12137fadfdc5eb838cd33edabcf36ac0b775609d7303971d52755e1335928a559973fe26211ce3ac9a8599ee75c77a978b44d1d7114437a922a8911d9016aceb",
      "name": "PKC",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:PLC)",
      "function": "Protein",
      "id": "a954cf31d48b6ddffaacdf9ac551464d6edda5fead07120c8d6453a89aab5a325ac1795b97e6993441005e73dd31fed063aa1c7c5b0b2ac77d1783fc8006e68c",
      "name": "PLC",
      "namespace": "FPLX"
    },
    {
      "bel": "p(HGNC:ACHE)",
      "function": "Protein",
      "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f",
      "name": "ACHE",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:APP)",
      "function": "Protein",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc",
      "name": "APP",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHAT)",
      "function": "Protein",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213",
      "name": "CHAT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHAT, pmod(Ph))",
      "function": "Protein",
      "id": "15538f34685d662b2f571a385368a154054df320ba912f0dc2e19cbf3af05b2e0e982a07bf39469dd6efc9c2bd75c8b76b1e58ada9d464ab8ff8c734e6353278",
      "name": "CHAT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:CHRM1)",
      "function": "Protein",
      "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
      "name": "CHRM1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM2)",
      "function": "Protein",
      "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5",
      "name": "CHRM2",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM3)",
      "function": "Protein",
      "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff",
      "name": "CHRM3",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM4)",
      "function": "Protein",
      "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969",
      "name": "CHRM4",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM5)",
      "function": "Protein",
      "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b",
      "name": "CHRM5",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA1)",
      "function": "Protein",
      "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f",
      "name": "CHRNA1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA10)",
      "function": "Protein",
      "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645",
      "name": "CHRNA10",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA2)",
      "function": "Protein",
      "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237",
      "name": "CHRNA2",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA3)",
      "function": "Protein",
      "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c",
      "name": "CHRNA3",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA4)",
      "function": "Protein",
      "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0",
      "name": "CHRNA4",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA5)",
      "function": "Protein",
      "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192",
      "name": "CHRNA5",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA6)",
      "function": "Protein",
      "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe",
      "name": "CHRNA6",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA7)",
      "function": "Protein",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99",
      "name": "CHRNA7",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA9)",
      "function": "Protein",
      "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04",
      "name": "CHRNA9",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNB1)",
      "function": "Protein",
      "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770",
      "name": "CHRNB1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNB2)",
      "function": "Protein",
      "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e",
      "name": "CHRNB2",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNB3)",
      "function": "Protein",
      "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca",
      "name": "CHRNB3",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNB4)",
      "function": "Protein",
      "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea",
      "name": "CHRNB4",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRND)",
      "function": "Protein",
      "id": "0fc12a3743f6213b0a8c9854f102f96f98b6d4ca5f6b93243215c6be9ef59d1071e4a981dfef35497424c052ed7d381aad79e113dad69e8c322a85d581ef69e9",
      "name": "CHRND",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNE)",
      "function": "Protein",
      "id": "be917968e1fe7473af686feb02038ad337b17130e7fb40bbeb5ca267ea2629061419099f77345afa3e5418433df2b5cb560b2d7e2fa3a3d936002d4a84d9580e",
      "name": "CHRNE",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNG)",
      "function": "Protein",
      "id": "fdc2324c7ab13b542120da2e930dae1aa2c84562e3bc9a659ddf97ae7412bf4cd7e8ad8fa72eca411b79eb3b1dc8c21dbdeb575bf3d6015c33aae8e21ca0cdf8",
      "name": "CHRNG",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "function": "Protein",
      "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c",
      "name": "GSK3B",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "function": "Protein",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1",
      "name": "MAPT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))",
      "function": "Protein",
      "id": "ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "hyperphosphorylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "function": "Protein",
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, var(\"?\"))",
      "function": "Protein",
      "id": "40a1fcd2e6b4af4d7f275f7ffae5cd34aff043c40297e912ed0e45c5a645d1abe2b717042d39ef0fd11ffa06c96785d31a8c7af123db21c2162d4e6ab59b9729",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:SLC18A3)",
      "function": "Protein",
      "id": "54407dc029292e71e6aa6d83b76ba173d7a64aded707423b0c2afbe6e4fcdba7a178ba1ded256b115be7cba323d1f3f68060181bc944a73f6d8e08ff3245397d",
      "name": "SLC18A3",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:SLC18A3, pmod(Ph))",
      "function": "Protein",
      "id": "d54a1a4a5862c9bd446292e2ab7ba4ada8f68272e18acafeda777aa31694a2a7f31573839ff79b44c902c90cf1f123ce98b995890d4750f44c568560685bd55a",
      "name": "SLC18A3",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:SLC5A7)",
      "function": "Protein",
      "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50",
      "name": "SLC5A7",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:SYP)",
      "function": "Protein",
      "id": "b3e408e89a46312126a4fd54c584f1e2cfb020273dcb194206b6813fd13e28c899a0127c25a8b5a407f76aef8a4ea42f4f74375f5e67831de6129644f3336550",
      "name": "SYP",
      "namespace": "HGNC"
    },
    {
      "bel": "p(INTERPRO:\"G-protein alpha subunit, group I\")",
      "function": "Protein",
      "id": "565d5a0ce05389cc28d32063238cc00ce7632812ed30abd3835743988317db88f8b40881c918c9a9216139a14c4a046cb4ee8d4abdd55fa5cc9ed22b77a1075a",
      "name": "G-protein alpha subunit, group I",
      "namespace": "INTERPRO"
    },
    {
      "bel": "p(INTERPRO:\"G-protein alpha subunit, group Q\")",
      "function": "Protein",
      "id": "73c6996c8615bbf150d78406fd9275ecc9b8db50afb3ca5395d0ce330bdc377560359f7a3e54dcdeef7111a791572d0e77edbb7780e39ba9a2cc56f6d5defb77",
      "name": "G-protein alpha subunit, group Q",
      "namespace": "INTERPRO"
    },
    {
      "bel": "p(MGI:App)",
      "function": "Protein",
      "id": "78d5e866274e31ff2b09ef6663cb084c62dad139135478daf1645a32988a8214b14330f44be626991077159244c9e35920dcc0025af376746275c215fceafca6",
      "name": "App",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:App, var(\"?\"))",
      "function": "Protein",
      "id": "46ac7e8068b43e3b0e5cf5fa539ff95e6608c883c30f4262372ad44d40949680df0fdc8e6115117e8756273e2906cbc0bb391ea60bdd80210c61e08b26d8130c",
      "name": "App",
      "namespace": "MGI",
      "variants": [
        {
          "identifier": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(MGI:Chrm4)",
      "function": "Protein",
      "id": "c5078486b54ee1c2b9f11e99715457719771e8c62d17d9b9357b7b0bb3928f9f14c5c1c4267f7a2c20cf42c7b2eca175d6b082a34a3a2b614fdb25a7c8506301",
      "name": "Chrm4",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Slc18a3)",
      "function": "Protein",
      "id": "63dd8e697245b42342d6a9c653698c9a6339983e6f4d2e1adc767ddec13128239bbd3efff08949718e192759bcd57fd8ddea791c07506d8d56cad490cc496b57",
      "name": "Slc18a3",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Slc5a7)",
      "function": "Protein",
      "id": "6ca22d2522fb264522601483416fdf83e3e4b32ed1963b7e925d113b08567e058de62e2d468885bf59c46b9e0db5c25ec99f7e0ad7b9847f5d26b3bb7db1d2d7",
      "name": "Slc5a7",
      "namespace": "MGI"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "function": "Pathology",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541",
      "name": "Alzheimer Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Amyotrophic Lateral Sclerosis\")",
      "function": "Pathology",
      "id": "5e56d7b5172af0ae281c2f920b132d7b2263ae5eff7b0f1c9a22347914d8c169c79314aa7738c7e68cf75fac198de894bff58cb9fd4a0cb95ab434310fa07daa",
      "name": "Amyotrophic Lateral Sclerosis",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Cognitive Dysfunction\")",
      "function": "Pathology",
      "id": "bd78fa3131dd9ef6067a5fe3ee8689c946c79d0da1bedb054d1f4400b9ad0d3ae041837faa0fbacee0af5a57a4cd343d11e73fd53fd05269e3558803a56df69c",
      "name": "Cognitive Dysfunction",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Down Syndrome\")",
      "function": "Pathology",
      "id": "3c70bf952a4a541caab3c832e97814c7d87b5c568cc2225ad985dab51802bf5d41c75c20298514df6338380b564189e309d158ae0b7d7729e949a13e9d0f024c",
      "name": "Down Syndrome",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Huntington Disease\")",
      "function": "Pathology",
      "id": "1879e0f73bb6f3f680c5793e5c3b9370792a52545c46d4ee9f41a8ef46edd5ba61400e77effb39bd0d1e7f3de6470e091c5d8e6c5beed8d780456b6740a4406c",
      "name": "Huntington Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Mood Disorders\")",
      "function": "Pathology",
      "id": "d95abb5844e33e30167f0730751de5ae4022e50ae8d043f4c70e0f2db1fa8ded1a44d79407f846ac0660fb47b3ca13b24eca088816afc2992ed2ed454c415008",
      "name": "Mood Disorders",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Neuromuscular Diseases\")",
      "function": "Pathology",
      "id": "7345fb9aff22fc85d5dcd2ec44717e63ed6fdc2b7d979ab626303664a5f584154c6f9fbb56a6899f2ec7f9c55a561937cb5d83bb5fc8217622577126c4deef0c",
      "name": "Neuromuscular Diseases",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Olivopontocerebellar Atrophies\")",
      "function": "Pathology",
      "id": "c16073e6a973231d9adabf34e58694576c97ce0b1e1cf016f42d8b3d92aad43b8fb5c87876c91cdb20087805b305fddf6da77e1cee2dabdc9e533860bc4e91d3",
      "name": "Olivopontocerebellar Atrophies",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Parkinson Disease\")",
      "function": "Pathology",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0",
      "name": "Parkinson Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Psychomotor Agitation\")",
      "function": "Pathology",
      "id": "3fd8c0d077f03e4ccf107386d0cf4b288acc7062b8ad86e7c5deade821d379b76b83683a98ec436a52d22ab2ffa764fd2b5d5fad56f9a485cf5cab429c0b9cf4",
      "name": "Psychomotor Agitation",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Supranuclear Palsy, Progressive\")",
      "function": "Pathology",
      "id": "06432576e845db5beb8ae7a4c0ae23454b691ca1773f3467bbd58f6ce3d484e768e57b6abbc21258bd43941d8ed10874fa0d45b24d91638ed7e42dcb0e5c7dd1",
      "name": "Supranuclear Palsy, Progressive",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Apathy)",
      "function": "Pathology",
      "id": "82471956361de9bdd217a79180c879a6c5bff20156a1e5faf43108358b5066aa4d692e888a527701bdbb63a5efdd28ba956f0c84cb0d186e41bd9629eb17dabb",
      "name": "Apathy",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Attention)",
      "function": "Pathology",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036",
      "name": "Attention",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Death)",
      "function": "Pathology",
      "id": "7277084fc3a1b0e377445b9052c02ac77fa754286debbdf8cfb948a489cda1bbfabab27531dc1a81026f92c278772709598e2982fd523d37d8d9b888532f8d63",
      "name": "Death",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Dementia)",
      "function": "Pathology",
      "id": "64388ba3ecebbe4d33fb76bedff9f458276b3ae72f47d401c6852d7f9d7c2abf4b2c4cfb899133f8c6ef9f7eff00a84697a1719fa10fed2e67ec00e97d00ed65",
      "name": "Dementia",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Depression)",
      "function": "Pathology",
      "id": "1db8d744eac9b5ac408852b1889bb0b09e0054ea091932f1aa44aeeab0ea1b3825912c55c72fb2d25d5848e77d62b1c6a1df2063a2f25ae03e5ca30085922799",
      "name": "Depression",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Hallucinations)",
      "function": "Pathology",
      "id": "ad73f79878286e99e48ad8b2ff196bd160666327c138014eae6150c76c71e650c37b2e6e083ba61dfda68dd41a788462fb101c654e6ad160cb434a2076b5df14",
      "name": "Hallucinations",
      "namespace": "MESH"
    },
    {
      "bel": "rxn(reactants(a(CHEBI:\"acetyl-CoA\"), a(CHEBI:choline)), products(a(CHEBI:acetylcholine)))",
      "function": "Reaction",
      "id": "67e4f589cdce9497a0a43da03a8a402f89eb6cbd8d585bdd7e3d9026082992e885b82103d791702e1926577a12111ec9021e85e2923ffe51f46285bfce1b08a6",
      "products": [
        {
          "bel": "a(CHEBI:acetylcholine)",
          "function": "Abundance",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62",
          "name": "acetylcholine",
          "namespace": "CHEBI"
        }
      ],
      "reactants": [
        {
          "bel": "a(CHEBI:\"acetyl-CoA\")",
          "function": "Abundance",
          "id": "a5fa305d2e2001d715f893ae6c2d622f7e9190eff20a4c42d6ac7af0177896d9464cdd5304827d22ac2fce8b653837ad54d0a95422b99f8fbf8e348571b0e739",
          "name": "acetyl-CoA",
          "namespace": "CHEBI"
        },
        {
          "bel": "a(CHEBI:choline)",
          "function": "Abundance",
          "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee",
          "name": "choline",
          "namespace": "CHEBI"
        }
      ]
    },
    {
      "bel": "rxn(reactants(a(CHEBI:acetylcholine)), products(a(CHEBI:acetate), a(CHEBI:choline)))",
      "function": "Reaction",
      "id": "ecc251bc346f68dfb6e1f0399d0b3f1ef4cea53f93d67532489ed66c29c326b854fd1ccf38ddd6923d9a3323e1f475b7590ab54136537a9383c13c6d127254fe",
      "products": [
        {
          "bel": "a(CHEBI:acetate)",
          "function": "Abundance",
          "id": "d5ded90176d5afa9f66d7ba0409d88511fae64124dd5180c6295d21039a13c0acfa4ca0169c04feb91a4195659923665085980b3745f5473e1b4e88b5c54686f",
          "name": "acetate",
          "namespace": "CHEBI"
        },
        {
          "bel": "a(CHEBI:choline)",
          "function": "Abundance",
          "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee",
          "name": "choline",
          "namespace": "CHEBI"
        }
      ],
      "reactants": [
        {
          "bel": "a(CHEBI:acetylcholine)",
          "function": "Abundance",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62",
          "name": "acetylcholine",
          "namespace": "CHEBI"
        }
      ]
    }
  ]
}